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The mitogen activated protein kinases (MAPK) are a large and diverse family of 
protein kinases, contributing to the cells ability to respond to external stimuli 
by relaying messages in a well orchestrated way until they reach their final 
destinations. This is achieved through successive phosphorylation events. One 
member of this large family is mitogen activated protein kinase activated 
protein kinase 5 (MAPKAPK5/MK5), which is activated by the upstream atypical 
MAPKs extracellular signal-regulated kinases 3 and 4 (ERK3 and ERK4), and 
possibly also the conventional MAPK p38MAPK. MK5 has been shown to be 
implicated in F-actin rearrangement through phosphorylation of heat shock 
protein 27 (HSP27), tumor suppression through at least two different pathways 
and cell cycle arrest in response to energy depletion. There has been done 
relatively little research on this protein, and  few bona fide substrates for MK5 
are known, although knowledge is emerging. One possible interaction partner 
for MK5 is DNAJB1, which has been shown to be phosphorylated by MK5 in 
vitro. DNAJB1 is a member of the heat shock protein 40 (HSP40) family/DNAJ 
family, which is a subunit of the much larger heat shock protein superfamily. 
Heat shock proteins mostly function as chaperones and co-chaperones in the 
cell, assisting in the maintenance of protein homeostasis, by refolding or 
degrading misfolded proteins. Conditions of stress in the cell can lead to 
increased levels of misfolded proteins, which in turn are thought to initiate the 
increased transcription of heat shock proteins observed in stressed cells. 
DNAJB1 mainly serves as a co-chaperone for heat shock protein 70, and has 
been implicated to play a role in various types of cancer and 
neurodegenerative disorders.
In this study we demonstrated that MK5 phosphorylates DNAJB1 in vitro, and 
that Tyrosine residue 6 and Serine residues 149, 151 and 171 in DNAJB1 are in 
vitro phosphorylation sites for MK5. Our results also indicate that other 
phosphorylation sites may be present. Further experiments are needed to 
elucidate the in vivo potential of these phosphoacceptor sites. We also found 
that MK5 and DNAJB1 exist in complexes. This interaction proved hard to 
reproduce, indicating that it might be of a transient nature, or perhaps a 
product of non-physiological conditions. We also showed that both proteins 
localize mainly to the nucleus in resting cells, when ectopically expressed, and 
that DNAJB1 seems to downregulate the level or the transcriptional activity of 
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1 Introduction
1.1 Protein kinases and signal transduction
Living cells are subject to a variety of chemical and physical stimuli from their 
immediate environment. In order for a cell to survive and function normally, it 
needs to respond to these stimuli in an appropriate manner. To achieve this, 
the extracellular signals need to reach their intracellular destinations. Such 
conversion from an extracellular signal to an intracellular response is referred 
to as signal transduction, and is often mediated by reversible phosphorylation 
of target proteins by protein kinases and protein phosphatases through a 
signaling cascade (Figure 1).
Protein kinases are responsible for most of the signal transduction in 
eukaryotic cells, and are among the largest of protein superfamilies, 
comprising 1.5–2.5% of all genes. They control several cellular processes, such 
as metabolism, transcription, cell cycle progression, cytoskeletal 
rearrangement and cell movement, apoptosis and differentiation [2].
1.1.1 The MAPK signaling pathway
The MAPK signaling pathway consists of individual components called MAP 
kinases (mitogen activated protein kinases). These kinases constitute a large 
family of Serine/Threonine kinases that regulate a myriad of cellular processes. 
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Figure 1: Schematic illustration of signal transduction 
relayed by protein kinases. The figure is adapted from [1]
As their name implies, the first group of signals that was identified as 
stimulators of the MAPK pathway, were mitogens. Others soon followed, like 
UV-irradiation and cytokines [3]. MAPKs are among the most ancient signal 
transduction pathways, and are widely conserved throughout evolution in a 
wide range of physiological processes. Their importance in cellular processes is 
underscored by the fact that all eukaryotic cells possess multiple MAPK 
pathways [4]. 
1.1.1.1 The MAPK family members
So far, 14 MAPKs have been characterized in mammals. These are divided into 
seven groups, four of which comprise the so-called conventional MAPKs and 
three that constitute the atypical MAPKs [4]
The conventional mammalian MAPK pathway is a three-tiered cascade 
composed of a MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K) and a 
MAPK (Figure 2). MAPK members of this group are; extracellular signal-
regulated kinases 1/2 (ERK1/2), c-Jun amino (N)-terminal kinases 1/2/3 
(JNK1/2/3), p38MAPK isoforms (α, β, γ, δ) and the big MAPK (BMK1/ERK5).
The atypical MAPKs, which are not organized in the conventional tripartite 
module, comprise ERK3/4, ERK7 and Nemo-like kinase (NLK) [5].
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Figure 2: MAPK signaling cascades and subsequent activation of MAPKAPKs. Dotted 
lines indicate that substrate regulation by the respective kinase remains to be 
thoroughly demonstrated. MK5, the MAPKAPK investigated in this study, is circled.  
The figure is adapted from [4].
1.1.1.2 MAPK structure
The MAPKs have an N-terminal and a C-terminal lobe, which are connected by 
a hinge-region. The gap between the N- and C-terminal lobes forms the 
catalytic site, which, in unphosphorylated MAPKs, is blocked by an a-helix. 
Upon phosphorylation by an upstream kinase, the gap opens, exposing the 
catalytic site, and thus activating the kinase [3].
1.1.2 MAPK-activated protein kinases
Both conventional and atypical MAPKs can phosphorylate not only non-protein 
kinase substrates, but also another family of protein kinases, referred to as 
MAPK-activated protein kinases (MAPKAPs). So far, 11 human MAPKAPs have 
been identified, and divided into five subfamilies consisting of several members 
(Figure 3). These families comprise the p90 ribosomal-S6-kinases (RSK1/4), 
the MAPK-interacting kinases (MNK1 and 2), the mitogen- and stress-activated 
kinases (MSK 1 and 2), the MK2/MK3 subgroup and MK5 [5]. 
1.1.2.1 MK5/PRAK
The MAPKAP5, or MK5, is the main focus of this thesis. This kinase was 
originally discovered in 1998 as a mouse expressed sequence tag by searching 
a database for sequences with a high degree of homology to MK2 [7]. Later 
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Figure 3: Phylogenetic tree of the human MAPKAPKs 
based on alignment generated by the CLUSTAL X 
program. MK5 isoforms A and B are circled. The figure is  
adapted from [6]
that same year, an independent research group reported the isolation of a 
p38MAPK regulated and activated kinase, PRAK, which turned out to be the 
human homologue of MK5 [8].
MK5 is extremely well conserved within the animal kingdom, and present in all 
vertebrates examined, including mammals, birds, reptiles and fish. This means 
that both ectothermic and endothermic animals possess an MK5 protein with 
high sequence homology, suggesting that this protein may possess catalytic 
activity over a wide range of temperatures [5].
Humans express two isoforms of MK5, as a result of differential splicing. The 
two isoforms differ by only two additional amino acids in the C-terminal of the 
larger variant, and are designated MK5A (473 amino acids) and MK5B (471 
amino acids). It is not known whether these two isoforms exert different 
functions in the cell [5].
1.1.2.1.1 Sequence and motifs
MK5 shares approximately 45% and 46% sequence identity with MK2 and MK3 
respectively. In contrast, MK2 and MK3 share approximately 75% sequence 
identity with each other. This contrast in homology is probably due to the 
unique 100 amino acid C-terminal tail of MK5 [3] (Figure 4). MK2, MK3 and 
MK5 all contain the conserved regulatory phosphorylation motif LXTP in the 
activation loop between kinase subdomain VII and VIII [2]. This is represented 
by T182 in MK5. MK2 and MK3 both contain additional regulatory sites between 
the catalytic domain and the C-terminal regulatory domain. This is not the case 
for MK5. Nor does MK5 contain the N-terminal Proline-rich region which is 
present in both MK2 and MK3 [9]. However, all three proteins contain nuclear 
localization signals (NLS) and nuclear export signals (NES) in their C-terminal 
domain, and, interestingly, in MK5 these signals overlap [10]. The NLS of MK5 
also overlaps with the p38MAPK docking site, and consequently, binding of 
p38MAPK prevents nuclear localization of MK5 [3]. The 100 amino acid C-
terminal extension previously mentioned is thought to play an auto-inhibitory 
role, and is, at least, required for interaction with ERK3 and ERK4 [10].
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Figure 4: Schematic illustration of the primary structure of MK2, MK3 and MK5. 
The figure is adapted from [11]
1.1.2.1.2 Regulation of subcellular localization 
Subcellular localization of MK5 is regulated by several factors, including 
NLS/NES, docking interactions and phosphorylation. Several studies have 
shown that both endogenous and ectopically expressed  MK5 reside 
predominantly in the nucleus of resting cells, but seem to be able to shuttle 
between the cytoplasm and the nucleus [5]. 
Stimulation of the p38MAPK pathway has been shown to cause nuclear exclusion 
of MK5, and p38MAPK is known to phosphorylate MK5 in vitro. Recent results 
suggest that different isoforms of p38MAPK direct MK5 to different subcellular 
localizations. MK5-p38α complexes are exclusively found in the nucleus, whilst 
MK5-p38β complexes reside in the cytoplasm [12]. However, the role of p38MAPK 
in MK5 regulation is still disputed. Endogenous MK5 could only be regulated by 
ectopic expression of p38MAPK, and binding of endogenous p38MAPK  and 
exogenous MK5 is weaker compared to p38MAPK interaction with other 
substrates. In addition, the activity of MK5 is not significantly increased upon 
stimulation of the p38MAPK pathway, and no interaction between endogenous 
MK5 and p38MAPK has ever been detected [2].
Co-expression of MK5 with both ERK3 and ERK4 leads to nuclear export of 
MK5, and kinase activity of neither MK5 nor ERK3/4 seems to be important for 
the subcellular relocalization, indicating that interaction rather than kinase 
activity of either protein is responsible for the subcellular redistribution of MK5 
[5].
Kostenko et al. showed that activation of cAMP/PKA (protein kinase A) pathway 
by Forskolin led to transient nuclear export of endogenous and EGFP-tagged 
MK5. No such redistribution was observed in PKA-deficient cells. NLS-tagged 
PKA remained in the nucleus, while MK5 was still exported, indicating that PKA 
and MK5 do not leave the nucleus in a complex. Serine 115 in MK5 was 
identified as PKA phosphoacceptor site. Substitution of Serine 115 to Alanine 
led to an MK5 mutant that no longer translocated upon cAMP/PKA activation, 
while a phosphomimicking S115D mutant was distributed in both nucleus and 
cytoplasm even in the absence of activated PKA [13].
1.1.2.1.3 Activation
MK5 has proven to be phosphorylated and activated by p38MAPK α and β in vitro, 
but an in vivo connection has not yet been established. In vivo activation by 
ERK3 and ERK4 on the other hand is undisputed, but the physiological 
implications so far remain unknown. Recent studies indicate that p21 activated 
protein kinases, PAK1 and PAK2  could act as upstream activators of ERK4, and 
thereby as indirect activators of MK5. Phosphorylation of Serine 115 by PKA 
leads to activation and nucleocytoplasmic redistribution of MK5 and subsequent 
phosphorylation of heat shock protein 27 [5].
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1.1.2.1.4 Substrates and physiological roles
As previously mentioned, MK5 has been shown to phosphorylate HSP27 both 
in vivo and in vitro. Kostenko et al. showed that depletion of HSP27 or over-
expression of a non-phosphorylatable HSP27 mutant ablated PKA/MK5 
triggered F-actin remodeling, as established by Gerits et al. [14], suggesting 
that MK5 is involved in HSP27-controlled F-actin dynamics in response to 
activation of the cAMP-dependent protein kinase pathway [15].
Recently, MK5 has been shown to phosphorylate and thereby activate the 
transcription factor FoxO3a. Upon phosphorylation, FoxO3a binds to and 
activates the promoter that controls expression of the  precursor RNA of miR-
34b and miR-34c, which target the three prime untranslated region (3' UTR) of 
Myc, thereby repressing translation. The Myc oncoprotein is a central regulator 
that stimulates cell growth and proliferation in response to extracellular 
signals. Downregulation of Myc is essential to ensure cell cycle arrest and 
survival of cells in response to DNA damaging agents. MK5 and Myc are 
engaged in a negative feed-back loop, with Myc binding to the MK5 promoter, 
thereby enhancing expression of MK5 [16]. Aberrant Myc expression plays a 
central role in oncogenesis. MK5 was observed to be downregulated in 
colorectal tumor cells compared to normal cells, whilst for Myc, the situation 
was the opposite, indicating a role for MK5 as a tumor suppressor through 
downregulation of Myc.
MK5 has also been shown to function as a tumor suppressor in vivo by 
mediating senescence upon activation by p38MAPK in response to oncogenic ras. 
MK5 deficiency in mice displayed enhanced dimethylbenzanthracene (DMBA) 
induced skin carcinogenesis. This coincided with compromised senescence 
induction [17]. DMBA is a well-characterized mutagen that causes skin tumors 
that are 90% positive for ras-mutations [4]. The results of the study suggest 
that MK5-mediated senescence likely suppresses skin carcinogenesis at the 
tumor promotion stage by preventing proliferation of genetically altered cells, 
such as those containing the activating ras-mutations. The authors suggest 
that  the tumor-suppressing effect of MK5 is likely due to its ability to modulate 
p53 activity through direct phosphorylation of Serine37. They propose that 
phosphorylation of p53 by MK5  in response to activation of p38MAPK by ras 
plays an important role in ras-induced senescence and tumor suppression [17].
Another way in which MK5 may mediate cell growth arrest, is by 
phosphorylation of ras homolog enriched in brain (Rheb). This is a small G 
protein, which is one of the key regulators of mammalian target of Rapamycin 
Complex 1 (mTORC1). mTORC1 regulates cell growth in response to different 
signals. The group of Han recently discovered that certain forms of energy 
starvation caused activation of p38βMAPK and phosphorylation of T182 and 
thereby activation of MK5. MK5 can bind and phosphorylate Rheb at Serine130 
in vivo. This phosphorylation severely impairs Rhebs ability to bind and retain 
GTP, which again inhibits mTORC1 [5]. 
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Both ERK3 and ERK4 are known iv vivo substrates of MK5, but the exact 
physiological consequences of MK5/ERK3 and MK5/ERK4 complex formation 
are still not known [5]. Certain observations suggest that ERK3 may play some 
roles in tumor suppression, and there is the possibility that MK5 may be an 
important ERK3 effector protein mediating these effects [4].
1.2 Heat Shock Proteins
Heat shock proteins (HSPs) were originally identified as  stress-responsive 
proteins required to deal with proteotoxic stress, i.e. they are upregulated 
upon, and protective against situations that increase the fraction of proteins 
that are in a fully or partially unfolded state. Such misfolded proteins increase 
the risk of protein aggregates, harmful to cellular processes. It is however not 
only conditions of stress that challenge the cellular protein homeostasis, but 
also numerous normal cellular processes, such as translation and transport 
over membranes [18]. Thus, HSPs are also present at lower concentrations in 
the cell under perfectly normal conditions, ”monitoring” the cell.
The HSPs make up a group of structurally unrelated proteins broadly classified 
into six major families based on their relative molecular mass in kiloDaltons: 
HSP110/HSPH,  HSP90/HSPC, HSP70/HSPA, HSP60/HSPD, HSP40/DNAJ and 
small heat shock proteins sHSP/HSPB. Each family consists of several 
members. These all play a prime role in protein homeostasis by binding to 
substrates at risk, keeping them in a conformation either competent for 
refolding or degradation. As such, they belong to a much larger superfamily of 
chaperones [18].
Increase in expression of HSPs is transcriptionally regulated, and is usually 
induced by heat shock factor (HSF) as shown in Figure 5.
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Various diseases challenge the normal function of the cell, and induce a variety 
of stress-responses. Protein conformational diseases, acute and chronic renal 
diseases, heart diseases and various aspects and types of cancers show 
involvement of different types of HSPs. For instance, HSPs are over-expressed 
in a wide range of human cancers, conferring resistance to cytotoxic therapies 
[19].
1.2.1 The HSP40/DNAJ family
All eukaryotic cells contain DNAJ proteins, and the human genome encodes at 
least 41 members of the DNAJ family [20]. The common domain that defines 
this family is the J-domain. This is a 70 amino acid sequence which consists of 
four helices in addition to a loop region between helix II and III that contains a 
highly conserved tripeptide of Histidine, Proline and Aspartic acid (HPD). 34 of 
the members in the DNAJ family contain the typical J-domains, while 7 bear 
only partially conserved J-like domains, but are still suggested to function as 
DNAJ proteins [20]. They are localized in different intracellular compartments 
and organelles, such as mitochondria, cytosol, endoplasmic reticulum, nuclei, 
endosomes and ribosomes [19].
The DNAJ family of heat shock proteins is known to stimulate the ATPase 
domain of HSP70/HSPA chaperones through their J-domains, and, as such, 
function as co-chaperones. HSPAs bind selectively to unfolded  hydrophobic 
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Figure 5: Schematic illustration of the HSF-regulated transcription of heat shock  
proteins.
regions of substrate polypeptides, and their activity is controlled by the cycle of 
ATP binding, hydrolysis and nucleotide exchange [20]. In its ATP-bound 
configuration, HSPA is in an open state with high association and dissociation 
rates for substrates, meaning low substrate specificity. Upon binding to a 
substrate, ATP is hydrolyzed, stabilizing HSPAs affinity for its substrate. This 
reaction is regulated by co-factors like DNAJs and CHIP. Subsequently, 
nucleotide exchange is stimulated (BAG-1, HSPB1 and HSPH), resulting in an 
ATP bound HSPA complex, followed by substrate release [18]. 
The DNAJ family can be further divided into three subfamilies based on their 
domain similarity to the E. coli DNAJ protein: type I HSP40/DNAJA, type II 
HSP40/DNAJB and type III HSP40/DNAJC. Each of these subfamilies contain 
several members.
1.2.1.1 DNAJA
The subfamily A DNAJ proteins are the closest human orthologues of the E. coli 
DNAJ protein. They contain a conserved N-terminal J-domain and a variable C-
terminal peptide-binding fragment [21]. Adjacent to the J-domain, a 
Glycine/Phenylalanine (G/F) rich region is believed to function as a flexible 
spacer that separates the N-terminal J-domain from the rest of the molecule. 
In the center of the molecule, there are four conserved Cysteine-rich repeats 
that fold around two zinc atoms, constituting two Zinc-finger motifs [18].
DNAJA proteins have proven to be able to bind non-native polypeptides by 
themselves, without the assistance of HSPA proteins, and suppress protein 
aggregation in the cell [19].
1.2.1.2 DNAJB
The subfamily B DNAJ proteins, similar to DNAJA, also contain the conserved 
N-terminal J-domain, the variable C-terminal domain, and the G/F rich spacer. 
They do not however harbor the Cysteine rich repeats with the Zinc-finger 
motifs.
DNAJB proteins can also bind to polypeptides by themselves, but can not 
prevent protein aggregation without the interaction of HSPA proteins [19]. 
1.2.1.3 DNAJC
The subfamily C DNAJ proteins also contain the conserved J-domain, but unlike 
DNAJA and DNAJB, it can be located at any position within the protein. The 
other conserved domains found in the DNAJA and DNAJB subfamilies are 
absent in DNAJC.
17
1.2.2 DNAJ proteins and their implication in disease
The DNAJB subfamily, and DNAJB1 (also named HSP40, Hdj1 or HSPF1) in 
particular, has been the most extensively studied mammalian DNAJ member. It 
has been shown to interact with both HSPA1A and HSPA8 in Luciferase-folding 
in vitro and in vivo [18]. 
Recently Zijlstra et al. found that levels of DNAJB members, in particular 
DNAJB1, correlate with the age onset of disease in patients with 
spinocerebellar ataxia type 3 (SCA3). Ataxia is a polyglutamine (Poly-Q) 
expansion disorder. These disorders are dominantly inherited adult-onset 
neurodegenerative diseases, and the disease corresponding Poly-Q proteins are 
aggregate-prone. The length of the expanded CAG (Q) repeat shows a strong 
inverse correlation with age onset, yet up to 50 % of the variation in age onset 
is determined by other additional factors. On the basis of the fact that several 
HSPs can modulate protein aggregate formation, Zijlstra and colleagues tested 
whether inter-individual differences in HSP expression could be related to CAG-
independent variations in the age onset of SCA3. They found that DNAJ 
members exclusively, and DNAJB1 in particular, showed a correlation to age 
onset. DNAJB1 levels were lowest in the patient group with the earliest age 
onset, and highest in the patients with the latest age onset. Furthermore, they 
found that aggregation of Ataxin 3 with a Poly-Q expansion was largely 
reduced by co-expression of DNAJB1. These findings indicate that DNAJ 
members might be contributors to the variation in age of onset of SCA3, and 
also highlights a possible use for DNAJB proteins as therapeutic targets [22].
DNAJ proteins have also been implicated in various types and aspects of 
cancer. To date, two DNAJA members, three DNAJB members and three DNAJC 
members of the HSP40 family have been reported to play certain roles in 
cancer biology. Some seem to act as tumor suppressors, such as DNAJB4 and 
DNAJA3. DNAJB4 expression has been shown to correlate inversely with cancer 
cell invasion ability, and inhibits several attributes of aggressiveness of lung 
adenocarcinoma, such as proliferation, tumorigenesis, motility and invasion. 
DNAJA3 has been shown to negatively regulate the migratory potential of 
cancer cells in skin cancer, colon cancer and glioblastomas. In addition, 
DNAJB6 has been found to be one of the most frequently under-expressed 
genes in ductal carcinoma when compared to normal breast epithelium. 
However, many HSP40 proteins are overexpressed in many types of cancerous 
tissues, conferring resistance to cytotoxic therapies. One such protein is 
DNAJA1, which has been reported to contribute to radiotherapy resistance in 
glioblastomas [19]. It seems DNAJ proteins play diverse roles in cancer 
biology, acting as both promoters and repressors of tumors and metastasis. 
Research in this field is emerging, but many questions remain to be answered 
in order to understand the mechanisms behind the involvement of DNAJ 
proteins in cancer biology.
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1.3 HSF1
The cellular response to diverse forms of of environmental and physiological 
stress involves the rapid transcriptional induction of target genes whose 
activity is regulated by different stress-specific trans-activators. The genes 
encoding heat shock proteins are such genes, and their transactivators are 
principally heat shock factors (HSFs). The heat shock factors are ubiquitously 
expressed and maintained in an inert, non-DNA binding state in unstressed 
cells. Upon exposure to stress conditions, the heat shock factors become 
activated to DNA-binding, transcriptionally active trimers, which promote 
transcription of heat shock genes (see Figure 5). The transcription of heat 
shock genes is rapid, yet transient, and, as Shi and colleagues proved, 
autoregulated by heat shock proteins. In their study they showed that 
overexpression of both HSP70 and the DNAJ family member Hdj1/DNAJB1 
resulted in negative regulation of HSF1 transcriptional activity. Both proteins 
interacted directly with the HSF1 transactivation domain with little effect on the 
DNA-binding or inducibly phosphorylated state of HSF1, indicating a function as 




2 Aims of the study
1. Investigate whether DNAJB1 and MK5 interact physically with each other.
2. Map putative in vitro phosphoacceptor sites for MK5 in DNAJB1.




3 Materials and methods
3.1 Materials
Table 1: Buffers and solutions used in this study
Buffer Contents/manufacturer Purpose
PBS 8 g NaCl, 0.2 g KCL, 1.44 g 
Na2HPO and 0.24 g KH2PO 
dissolved in 800 ml distilled H2O. 
Hcl to pH 7.4, distilled H2O to 1 
liter. [Sambrook, vol 3, appendix 
B]




PBST PBS with 0.1% Tween 20 Western Blotting
PBT PBS with 1% Triton X-100 GST purification





Clear Page  20 x running 
buffer
C.B.S. Scientific, working 
dilution: 1:20
SDS-PAGE
Nu Page 20 x running buffer Invitrogen, working dilution: 
1:20
SDS-PAGE
Blotting buffer 800 ml distilled H2O, 200 ml 
Methanol, 29 g Glycin, 5.8 g Tris 
base
Western Blotting
Blocking buffer 150 ml PBS, 7.5 g non-fat dry 
milk powder, 150 µl Tween 20
Western Blotting
10 x Washing buffer 100mM Tris HCl pH 9.5, 100 mM 
NaCl, 10 mM MgCl2, distilled H2O. 
Working dilution: 1:10
Western Blotting
CDP Star Buffer 5 ml DEA in 420 ml double 
distilled H2O, pH 9.5. Add 1 g 




50 x TAE buffer 242 g Tris base, 57.1 ml glacial 
acetic acid, 100 ml 0.5 M EDTA 
(pH 8.0), distilled H2O to 1 liter.
Agarose gel 
electrophoresis




LDS sample buffer 20 µl 4X NuPAge LDS buffer 




Coomassie Blue solution 0.25 g Coomassie brilliant blue 
R-250,  250 ml Methanol, 50 ml 
Acetic acid, 200 ml distilled H2O
Coomassie blue staining
Fixation solution 400 ml distilled H2O, 500 ml 
Methanol, 200 ml Acetic acid
Coomassie blue staining
Destaining solution 880 ml distilled H2O, 50 ml 
Methanol, 70 ml Acetic acid
Coomassie blue staining
Lysis buffer 50 mM Tris Hcl pH8, 150 mM 
NaCl, 1 mM EDTA, 1mM DTT, 200 
µl protease inhibitor cocktail
Co-immunoprecipitation
Tropix® lysis buffer Applied Biosystems Luciferase assay
PFA 0.8 % 0.8 g Paraformaldehyde 
dissolved in 9 ml distilled H2O. 
1M NaOH added dropwise unitl 
Paraformaldehyde dissolved, 1 
ml 10x PBS
Fixation of cells 
TBD buffer 10 mM Tris Hcl pH 7.5, 0.1mg/ml 
BSA, 1 mM DTT, distilled H2O
In vitro kinase assay
Kinase buffer 250 mM Tris Hcl pH 7.5, 100mM 
MgCl2, distilled H2O
In vitro kinase asay
Big Dye® Terminator v3.1 5 
x sequencing buffer
Applied Biosystems. Cat# 
4336697
DNA sequencing PCR
Neb buffer 1 Bio Labs, Cat# B7001S Restriction cloning
Neb buffer 2 Bio Labs, Cat# B7002S Restriction cloning
Neb buffer 3 Bio Labs, Cat# B7003S Restriction cloning
10 x cloned PFU reaction 
buffer
Stratagene, Cat# 600153-82 Site directed 
mutagenesis
10 x TA buffer 330 mM Tris-acetate (pH 7.8),
660 mM potassium acetate, 100 
mM magnesium
acetate and 5 mM Dithiothreitol 
(DTT)
Restriction cloning
10 x T4 DNA ligase buffer 
with 10 mM ATP
Bio Labs, Cat# B0202S Restriction cloning
Luciferase substrate Promega, Luciferase 1000 Assay 
System Cat# E4550 
Luciferase assay
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Table 2: Growth media used in this study
Growth medium Contents Purpose
LB medium 950 ml deionized H2O, 10 g bacto-
tryptone, 5 g yeast extract, 10 g 
NaCl, 5 N NaOH to pH 7.0 (~0.2 ml), 
deionized water to 1 liter
Growth of bacterial 
cultures for plasmid 
purification and GST 
protein purification
LB agar plate LB medium +  15 g bacto-agar per 
liter
Transformation of bacterial 
cells
NZCYM 950 ml deionized water, 10 g NZ 
amine, 5 g NaCl, 5 g bacto-yeast 
extract, 1 g casaminoacids, 2 g 
MgSO4· 7H2O, 5 N NaOH to pH 7 
(~0.2 ml), deionized water to 1 liter.
GST protein purification
SOC 950 ml deionized water, 20 g bacto-
tryptone, 5 g bacto-yeast extract, 
0.5 g NaCl, 20 mM glucose 10 ml 
250 mM KCL, 5 N NaOH to pH 7.0 
(~0.2 ml)




Standard Dulbecco's Modified Eagles 
medium (DME), 10% Fetal Bovine 
Serum (filtered), Penicillin 
(100U/ml), Streptomycin(100µl/ml)
Mammalian cell culture
FBS Heat inactivated Fetal Bovine Serum, 
Gibco 
Mammalian cell culture
Opti-MEM® A modification of Eagle's Minimum 
Essential Media, buffered with HEPES 
and sodium bicarbonate and 
supplemented with hypoxanthine, 
thymidine, sodium pyruvate, L-
glutamine, trace elements and 
growth factors. Gibco, Invitrogen.
Transient transfection
Trypsin/EDTA 0.05% Trypsin in EDTA Mammalian cell culture
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Table 3: Plasmids used in this study
Plasmid Comment Reference/source Purpose
pG5E1b-luc Luciferase reporter 
plasmid with five 
binding sites for the 
yeast transcription 
factor Gal4 cloned 
upstream of a 
minimal promoter, 
an Adenovirus E1b 
TATA-box driving a 
Luciferase gene





pGAL4-HSF1 DNA binding domain 




pM-MK5 Encodes a fusion 
protein containing 
the DNA binding 




pcDNA3 A vector for 
constitutive 
expression in a 
variety of 
mammalian cell 
lines.  Contains 
(CMV) enhancer-
promoter.















pDest15 Destination vector in 
the Gateway® 




pDestHA Destination vector in 
the Gateway® 




pDest3xFLAG Destination vector in 
the Gateway® 





pDest-EYFP Destination vector 
containing EYFP







pDest-ECFP Destination vector 
containing ECFP
























pDest3xFLAG-HSP40 DNAJB1 cloned into 
pDest3xFLAG by 
Gateway® system
This study Co-ip, Luciferase 
assays




pEGFP-MK5-L337A-NES Constitutively active 
MK5 wih additional 
NES-sequence
This group Confocal studies
pEGFP-HSF1 cDNA fragment 
encoding the mouse 
HSF1 ORF cloned 
between XhoI and 




pENTR1A-HSF1 HSF1 cloned into 
pENTR1A between 
EcorI and SalI





cloned into pENTR3C 
between KpnI and 
NotI






Amino acid 1-70 of 








Amino acid 71-105 









Amino acid 106-175 








Amino acid 176-245 








Amino acid 139-341 






































DNAJB1 with double 
mutation 
S149A_S151A









This study Gateway® 
cloning














pDest-EYFP-MK5L337A MK5L337A cloned 










This study Confocal studies
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Anti HA Mouse monoclonal IgG2bκ  that 
recognizes HA peptide 
sequence [YPYDVPDYA] 
derived from human influenza 
Hemagglutinin protein. 
Roche Co-IP
Anti-GFP Mixture of two monoclonal 
antibodies against GFP. IgG1κ
Source: mouse
Roche Co-IP
Anti HSP40 Polyclonal. Detects 










Mouse monoclonal  IgG1 raised 
against amino acids 294-473 
mapping at the C-terminus of 









Goat anti rabbit IgG 






Goat anti mouse IgG 




















carboxyl terminal sequence of 
human β-tubulin isotype III
Source: mouse




A high-affinity probe for F-
actin that is made from a 
phallotoxin conjugated with 
Alexa Fluor 594 dye.
Invitrogen Immunofluoroscence 
satining
DRAQ5TM Far-red fluorescent DNA dye 
that stains dsDNA/nuclei of 
live or fixed cells.
Biostatus limited Immunofluoroscence 
satining
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Table 5: Enzymes used in this study
Enzyme Manufacturer /catalog 
number (Cat #)
Purpose
Big Dye® Terminator v3.1 Applied Biosystems Sequencing PCR
PFU turbo Stratagene, Cat # 600252 Site directed mutagenesis
T4 DNA ligase Bio Labs, Cat # M0202S DNA ligation
Gateway® LR Clonase® II 
enzyme mix
Invitrogen, Cat # 11791020 Gateway® cloning
Dpn I Bio Labs, Cat # R0176S Site directed mutagenesis
Ecor I Promega, Cat # R601A Restriction digestion
Kpn I Bio Labs, Cat # R0142S Restriction digestion
Xho I Bio Labs, Cat # R0146S Restriction digestion
Xba I Bio Labs, Cat # R0145S Restriction digestion
Table 6: Primers used in this study (all primers were purchased from Sigma)
Primer Sequence Source Purpose

































Table 7: Commercial proteins used in this study
Protein Description Manufacturer Purpose
HSP40/DNAJB1 Recombinant full 
length human HSP40 
expressed in E.coli 
using an N-terminal 
GST-tag. >90% 
purity
Approximate MW = 
65kDa
SignalChem In vitro kinase assay
MK5/PRAK Human recombinant 
full-length protein 
Histidine tagged. 
Expressed in insect 
cells. Activated in 
vitro by GST-tagged 
MAPK14
Invitrogen In vitro kinase assay
Table 8: Transfection reagents used in this study
Transfection reagent Manufacturer Purpose
LipofectamineTM 2000 Invitrogen, Cat # 11668-
019
Transient transfection for 
subsequent Luciferase 
assays and confocal studies
Metafectene® Pro Biontex, Cat # T040-2.0 Transient transfection for 
subsequent Co-ip
Cell Line Nucleofector® kit V Lonza, Cat # VCA-1003 Transient transfection of 
PC12 cells
Table 9: Kits used in this study
Kit Manufacturer Purpose
Nucleobond®Xtra Midi kit Machery Nagel Plasmid purification, 
medium quantities
NucleoSpin® Plasmid kit Machery Nagel Plasmid purification, small 
quantities
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Table 10: Bacterial strains used in this study
Bacterial strain Description Purpose
Escherichia coli DH5α A recombination-deficient, 
suppressing, competent E. 
coli strain
Storage and amplification of 
different plasmid-vectors
Escherichia coli BL21 A protease deficient, 
competent E. coli strain
Storage and expression of 
GST fusion proteins
Table 11: Mammalian cell lines used in this study
Cell-line Organism Organ ATTC number Purpose
HEK293 Human Kidney CRL-1573 Transient 
transfection









3.2.1 Purification/extraction of plasmid DNA from bacterial cells
Pure plasmid DNA is essential in many experiments within the field of 
molecular biology. Genetically manipulated plasmids serve as vectors into 
which genetic elements of interest can easily be inserted, multiplied and 
expressed. By transforming such plasmid-vectors into competent bacterial 
cells, the copy number can easily be multiplied ten-thousand fold. In order to 
utilize this plasmid DNA in further studies, it needs to be separated from the 
genomic DNA and other cellular components. There are many commercially 
available kits that serve this purpose. In this study, two different protocols 
from Machery Nagel were used to perform extraction of plasmid DNA from 
bacterial cells. Both protocols are based on Alkaline lysis of the bacterial cells, 
followed by equilibration and loading onto a column consisting of a special, 
patented, silica-based anion-exchange resin. The column in the midi kit 
operates by gravity flow, while the column in the  NucleoSpin kit operates by 
centrifugal forces. Under acidic conditions, the resin in the column has an 
overall positive charge, which allows high affinity binding of the negatively 
charged phosphate backbone of DNA. A pH-shift to slightly alkaline conditions 
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neutralizes the positive charge of the resin, and pure plasmid DNA is eluted 
[26]. 
3.2.1.1 Plasmid DNA purification using Nucleobond®Xtra Midi kit from 
Machery-Nagel for High-copy plasmid purification [26].
1. 100 ml over night culture was prepared by scraping the frozen surface 
of bacteria stock* containing the desired plasmid with a sterile pipette 
tip, and adding the tip to a 500 ml flask with 100 ml LB medium 
supplemented with the appropriate selective antibiotic (Kanamycin or 
Ampicillin). Alternatively, 100 µl of a small starter culture made from a 
single colony on a freshly streaked agar plate was added to the culture 
flask.
2. The culture was then grown overnight at 37°C and on the shaker (220 
rpm) for 12 to 16 hours. 
3. Bacterial cells were harvested by centrifugation at 6000 x g for 10 
minutes at 4°C, and the supernatant was completely discarded by 
inverting the centrifuge flask.
4. The bacterial pellet was further completely resuspended by adding 8 ml 
Resuspension Buffer, RES, supplemented with RNaseA and pipetting the 
cells up and down. 
5. Cell lysis was then performed by adding 8 ml Lysis Buffer, LYS, to the 
suspension, and mixing carefully by inverting the tube 5 times. The 
mixture was incubated at room temperature for 5 min. 
6. In the meantime, a Nucleobond®Xtra column and filter was equilibrated 
by applying 12 ml Equilibration Buffer, EQU, along the rim of the filter, 
making sure the entire filter was wet. The column was then allowed to 
empty by gravity flow. 
7. The Lysis-suspension (step 5) was neutralized by adding 8 ml 
Neutralization Buffer, NEU, and immediately mixing by inverting the 
tube 10-15 times. No incubation is required.
8. Making sure the suspension was homogenous by inverting the tube 3 
times directly before adding it to the equilibrated column filter, the 
suspension was loaded onto the column, and the column allowed to 
empty by gravity flow. 
9. The filter and column were then washed by applying 5 ml of 
Equilibration Buffer, EQU, along the rim of the filter, and the column 
once more allowed to empty by gravity flow. 
33
10. The column filter was then discarded, and the column washed by adding 
8 ml Wash Buffer, WASH. 
11. Plasmid DNA was then eluted by adding Elution Buffer, ELU, collecting 
the eluate in a 15 ml centrifuge tube. 
12. 5 ml room temperature Isopropanol was next added for precipitation of 
the eluted plasmid, followed by vigorous pipetting up and down. 
13. The mixture was incubated for 2 min at room temperature, and then 
centrifuged at 15000 x g for 30 min at room temperature The 
supernatant was carefully discarded by inverting the tube.
14. The plasmid-DNA pellet was washed and dried by adding 2 ml room 
temperature absolute ethanol and spinned down at 15000 x g for 5 
minutes at room temperature. 
15. The supernatant was removed by carefully inverting the tube, and the 
tube was left to dry upside-down for 5-10 min. 
16. Finally, the DNA pellet was dissolved in 100 µl of TE buffer.
*Bacteria culture made from a single colony on a freshly streaked agar-plate mixed with 
glycerol (final concentration 15%) for cryo-protection and kept at -70°C for further use.
3.2.1.2 Miniprep of plasmid DNA using NucleoSpin® Plasmid kit from Machery 
Nagel
1. A culture in 3 ml LB medium + appropriate selective antibiotic was 
grown at 37°C and 220 rpm shaking over night (o.n.).
2. The following day, the culture was transferred to a microcentrifuge tube 
(eppendorf tube) and centrifuged for five minutes at 11000 x g in a 
standard benchtop microcentrifuge. 
3. The supernatant was discarded, and as much liquid as possible 
removed. 
4. 250 µl resuspension buffer (A1) was then added and the cells 
resuspended completely by vortexing or pipetting up and down. No cell 
clumps should remain in the suspension. 
5. Next 250 µl lysis buffer (A2 ) was added, and the suspension was mixed 
gently by inverting the tube 6-8 times, to avoid shearing of genomic 
DNA, and incubated at room temperature for up to five minutes. 
6. Then 300 µl Buffer A3 was added to neutralize the lysis reaction 
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mixture. The lysate was mixed thoroughly by inverting the tube 6-8 
times, and centrifuged at 11 000 x g for five minutes at room 
temperature. This step was repeated if supernatant was not clear.
7. A NucleoSpin® Plasmid Column was placed in a collection tube and a 
maximum of 750 µl of the supernatant was pipetted onto the column.
8. The column was then centrifuged for one minute at 11,000 x g, and 
flow-through discarded. 
9. Next 600 µl Buffer A4 supplemented with ethanol was added, and the 
columns centrifuged for 1 min at 11,000 x g. Flow-through was 
discarded, and the column placed in the empty collection tube. 
10. In order to dry the DNA, the column was centrifuged for 2 min. 
11. At the end of the centrifugation, the column was placed in an empty 1.5 
ml eppendorf tube, and supplied with 50 µl Elution buffer. This was 
incubated for 1 minute at room temperature, before centrifugation at 11 
000 x g for 1 minute.
12. The resulting suspension in the eppendorf tube now contained the 
purified plasmid DNA, and was kept at -20 C until evaluation of purity 
and concentration.
3.2.2 Evaluation of Plasmid DNA concentration and purity
Concentration and purity of plasmid DNA can be evaluated by two general 
methods; UV-spectrophotometry and Agarose gel electrophoresis. The most 
comprehensive approach is to use both methods.
In this study, for most DNA-preps, UV-spectrophotometric measurements were 
used. 
3.2.2.1 UV-spectrophotometry
DNA itself, and most of the common contaminants found in DNA preps, have 
absorbances in the region 230 nm to 320 nm. Measurement of the 
absorbances in this region thus allows measurement of the DNA concentration 
and provides information about the contaminant levels. 
Guanidium salts and Phenol used in the purification procedure absorb light 
strongly at 230 nm, Tyrosine and Tryptophan residues in proteins do the same 
at 280 nm, while DNA absorbs most strongly at 260 nm. High absorbances at 
230 nm indicate there might be carry-over from the preparation, and high 
absorbances at 280 nm indicate protein contamination. A good quality DNA 
35
sample should have a A260/A280 ratio of 1.7-2.0 and an A260/A230 ratio of 
greater than 1.5 [27].
3.2.2.2 Agarose gel electrophoresis
Agarose gel electrophoresis is a simple and highly effective method for 
separating, identifying and purifying DNA-fragments in the size-range 0.5 to 25 
kb. It also allows determination of the conformation of plasmid DNA. Plasmid 
DNA can occur in three forms: covalently closed circular (CCC), open covalent 
circular (OC) and linear. CCC DNA transfects better than OC and linear, so for 
transfection studies it is important that plasmid DNA is mainly in the CCC 
configuration. 
To do Agarose gel electrophoresis, first, a gel is prepared with an Agarose 
concentration appropriate for the size of the DNA fragments to be separated. 
Next, the DNA samples are loaded into the sample wells, and the gel run at a 
voltage  and time-period that ensures optimal separation of the fragments. 
Finally, the gel is stained, or if Ethidium Bromide has been incorporated into 
the gel, the DNA-fragments are visualized directly upon UV-illumination [28].
Protocol:
For a small gel (40 ml) of 1% Agarose
1. 0.4 g Agarose was added to 40 ml 1x TAE buffer (table 1) in an 
erlenmeyer flask, and heated in the microwave at full effect for 90 
seconds. The flask was swirled a couple of times, to ensure even mixing.
2. The mixture was cooled down to approximately 50 °C, before 2 µl 
Ethidium bromide (10 mg/ml) was added.
3. The gel was poured into a gel-mold, with a comb already in place, and 
any air bubbles were removed with a pipette tip.
4. The gel was left to solidify for at least 15 minutes.
5. The gel was next transferred to a running-chamber filled with 1 x TAE 
buffer.
6. 2 µl DNA-sample was supplied with 8 µl ddH2O and 2 µl 6 x loading 
buffer (table 1).
7. DNA-samples were applied to the sample wells in the gel.
8. 5 µl 1kb+ ladder was added to one of the wells, to serve as a reference 
for the size of the DNA-fragments.
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9. The gel was run at 90 V, 400 mA for approximately 45 minutes.
3.2.3 Mammalian cell culture techniques
A number of experiments in the field of molecular biology rely on the use of 
mammalian cell cultures to mimic/simulate living systems. There are a number 
of different cell lines to work with, derived from different species and different 
kinds of tissues. Each cell line displays their own characteristics, and different 
cell lines may require slightly different culture protocols. Cells can be cultured 
in a monolayer attached to the plastic surface of a culture vessel, or they can 
be grown in suspension. For this study, cells were cultured in the former 
manner.
3.2.3.1 Subculturing (splitting) of cells
When the cells grow confluent, space, oxygen and nutrients become scarce 
resources. If kept at such conditions, the cells will die, and detach from the 
surface of the culture vessel. To avoid such a scenario, the cells have to be 
subcultured regularly. This practice is also referred to as «splitting» the cells. 
The process involves detaching cells from the surface by Trypsin treatment, 
followed by reuspension of the cells in a small volume of culture medium, and 
finally transfer of a small volume of this concentrated cell suspension to a 
larger volume of fresh growth medium, thereby making the cell suspension 
«thinner», quite commonly by a order of ten. 
Protocol:
Before starting, PBS, normal growth medium and Trypsin were prewarmed to 
37 °C.
1. Growth medium was carefully aspirated by water suction.
2. Prewarmed PBS was carefully added, and the flask was swirled gently to 
cover the entire surface, thereby washing the cells thoroughly. PBS was 
then removed by water suction.
3. Trypsin in EDTA was added to the flask, and the flask put in the incubator 
for a few minutes, until cells had rounded up. The flask was then tapped 
gently against the palm of the hand in order to detach the cells from the 
surface.
4. The cells were then resuspended in fresh growth medium supplied with 
10% FBS and Pen-Strep.
5. 1 ml of this suspension was transferred to a culture flask already 
containing fresh growth medium.
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Amounts of medium, PBS and Trypsin are given in table 12.
Table 12: Cell culture volumes
Reagent Large culture flask Medium culture flask
Normal growth medium 30 ml 15 ml
PBS 10 ml 5 ml
Trypsin/EDTA* 1 ml 0.5 ml
Normal growth medium for 
resuspension
10 ml 5 ml
 * May vary according to cell line. Some cells, like HEK 293 detach very easily and do not 
require more than the volumes given in the table. Other cell lines, such as HeLa or PC12 cells 
may require larger volumes or higher concentrations to detach properly.
3.2.3.2 Seeding out cells for transient transfection
For different transfection procedures, different amounts of cells are needed. 
The optimal cell density for transfection is usually provided by the 
manufacturer of the transfection reagent. To calculate the number of cells in a 
cell suspension, a small drop was applied to the edge of a Bürker counting 
chamber, and cells were counted under a light microscope. 
3.2.3.3 Harvesting cells
3.2.3.3.1 For Co-immunoprecipitation
Cells were washed twice with prewarmed PBS.
Then, 300 µl lysis buffer was added, and the cells detached from the surface 
by scraping with a cell scraper. 
The resulting suspension was transferred to an eppendorf tube, and spinned 
down at 13 000 rpm for 10 minutes.
3.2.3.3.2 For Western Blot
Cells were washed twice with prewarmed PBS.
Then, 80 µl LDS sample buffer was added, and the cells detached from the 
surface by scraping with a cell scraper.
The resulting suspension was transferred to an eppendorf tube, and sonicated 
3 x 10 seconds, before denaturation at 70 °C for 10 minutes.
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3.2.3.3.3 For Luciferase studies
Cells were washed twice with prewarmed PBS.
Then, 100 µl Tropix lysis buffer supplied with 0.5 mM DTT was added, and the 
cells harvested by scraping with a cell scraper.
The resulting suspension was transferred to an eppendorf tube and spinned 
down at 13 000 rpm for 5 minutes.
3.2.4 GST-protein purification
The Glutathione S-Transferases (GSTs) represent a major group of 
detoxification enzymes. All eukaryotic species possess multiple cytosolic and 
membrane-bound GST isoenzymes [29]. These enzymes protect cells against 
toxic substrates by conjugating them to Glutathione, thereby neutralizing their 
electrophilic sites, and rendering the products more water-soluble. The 
Glutathione conjugates are metabolized further to Mercapturic acid and then 
excreted [30]. GSTs bind Glutathione with high affinity and specificity. The 
strength and selectivity of this interaction enables Glutathione-based affinity 
resins to effectively purify GST-tagged proteins. Such GST-tagged proteins 
(GST fusion proteins) are constructed by incorporating a GST gene into an 
expression vector, followed by cloning of a protein of interest into the vector, 
directly downstream of the GST gene. To ensure high levels of transcription of 
the resulting fusion protein, the expression vector usually contains  an easily 
inducible promoter, like the lac-promoter from E. coli. This promoter can be 
induced by the compound IPTG (Isopropyl β-D-1-thiogalactopyranoside). This 
compound is used as a molecular mimic of Allolactose, a lactose metabolite 
that triggers transcription of the lac operon. Induction of the promoter leads to 
transcription of the fusion protein. 
Protocol:
Prior to protein purification, Glutathione Sepharose beads were washed 3 times 
in PBT, and finally resuspended in PBT to a concentration of 50%. The beads 
were left at 4 °C for at least 2 hours prior to use.
Protease inhibitor cocktail was prepared by dissolving one tablet of protease 
inhibitor into 2 ml of distilled H2O.
1. 5 ml LB with Ampicillin was inoculated with protease deficient bacteria 
(BL21) carrying a plasmid vector containing the desired fusion protein.
2. The culture was grown o.n., and transferred into 50 ml NZCYM with 
Ampicillin.
3. The culture was then grown until OD600 = 0.6
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4. When OD600 = 0.6, 50 µl 1M IPTG was added (to make a final 
concentration of 1 mM), and the culture left to grow for two hours at 
room temperature.
5. The bacterial culture was then transferred to a 50 ml centrifuge tube, 
and spinned down at 4000 rpm for 20 min.
6. The supernatant was removed, and the bacterial pellet stored at -20 °C 
until further use.
7. Before carrying on with the rest of the procedure, the bacterial pellet 
was transferred to –70 °C overnight.
8. The pellet was then thawed on ice, and resuspended in 1 ml PBT + 200 
µl protease inhibitor cocktail + 10 µl 1M DTT (final concentration of 
10mM).
9. The suspension was next sonicated 3 x 10 seconds on ice, to disrupt the 
cell membrane, and release the intracellular contents. The lysate was 
transferred to an eppendorf tube, and then spinned down at 13 000 rpm 
for 10 minutes at 4 °C.
10. The supernatant, containing the intracellular proteins, was transferred 
to a new eppendorf tube, and 100 µl 50% Glutathione beads were 
added.
11. The tube was placed on a rotator at 4 °C for one hour.
12. The beads were then washed 3 x PBT followed by 3x PBS. After the last 
wash, as much supernatant as possible was removed.
13. GST-fusion proteins were eluted by adding 250 µl 5 mM Glutathione in 
50 mM Tris pH 8.0, and placing the tube on a rotator at room 
temperature for 15 minutes. Free Glutathione competes with the 
immobilized Glutathione on the beads for epitopes on the GST-part of 
the GST-fusion proteins, thus releasing them from the solid phase and 
into suspension. This step was repeated to obtain two eluates.
3.2.5 Evaluation of GST-protein purification by Coomassie Blue 
staining
It is important to evaluate the result of GST-protein purification, before moving 
on to further experiments. One way to do this is by Coomassie Blue staining. 
Coomassie Brilliant Blue is a dye that binds non-specifically to virtually all 
proteins. By subjecting the purified GST-fusion proteins to a SDS-PAGE (see 
section 3.2.6), followed by fixation and staining of the gel by a solution 
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containing Coomassie Brilliant Blue, all proteins in the sample can be visualized 
as blue bands appearing in the gel. By including a protein standard in the gel, 
the size of the individual protein-bands can be estimated, and conclusions 
drawn as to whether the purification was successful or not. This is, however a 
purely qualitative measurement of protein concentration. To obtain more 
accurate measurements of protein concentration, other methods must be 
applied.
1. Protein samples (eluates) were first subject to SDS-PAGE (see section 
3.2.6.1) 
2. The gel was transferred to a petri-dish containing Fixation buffer, and put 
on a shaker for 1 hour at room temperature.
3. The Fixation buffer was removed, and replaced with Coomassie Blue 
solution for 30 minutes.
4. The gel was then washed once with Fixation buffer, before destaining 
solution was added, together with a small piece of paper towel (to 
increase destaining).
5. The destaining solution was changed regularly, and the gel left to destain 
o.n.
6. The following day a picture was taken, and an assessment made as to 
whether the desired protein  was indeed enriched in the process, and 
whether it seemed to be present at sufficient concentrations.
3.2.6 SDS-PAGE
SDS-PAGE (Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis) is a 
technique that is used to separate proteins based on molecular mass.
The gel is made by polymerized acrylamide, which creates a meshwork that 
functions as a barrier to the movement of polypeptides. Smaller polypeptides 
will work their way through this meshwork quicker than larger ones, and so the 
polypeptides can be separated by size. Some gels have a constant 
concentration of acrylamide throughout the gel, while others have a graded 
concentration.
Native proteins harbor secondary, tertiary and sometimes quaternary 
structures, governed by their composition of differently charged amino acids. 
In their native conformations, two proteins of approximately the same size 
could potentially migrate through the gel at significantly different rates. To be 
able to separate the proteins in a sample based purely on their size, they need 
to be denatured. That means their secondary, tertiary and quaternary 
structures need to be eliminated, so that the polypeptide is linearized. This is 
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achieved by the addition of SDS to the samples. SDS is an anionic detergent 
which binds to the protein in a constant weight ratio of 1.4 g/g of polypeptide, 
giving the proteins a net negative charge in the process [31]. This negative 
charge is also important for the proteins' electrophoretic mobility. The negative 
charge allows migration from the cathode to the anode, “pulling” the proteins 
through the gel. 
3.2.6.1 Using  the Clear Page 10x10 cm SDS Cassette gels, 4-12%
The Clear Page gels were used to evaluate the result of GST-protein 
purification:
1. The gel was removed from the plastic, and rinsed in deionized water.
2. The wells were rinsed three times with Clear Page running buffer, and the 
gel mounted in the XCell SureLockTM Mini-cell. 
3. The inner chamber was filled with fresh running buffer, and the outer 
chamber filled with running buffer that had been used no more than two 
times before, but need not be fresh.
4. 15 µl of protein sample (eluate) was transferred to an eppendorf tube, 
and supplied with 5,5 4x NuPage LDS sample buffer and 2 µl 1M DTT.
5. The samples were then denatured at 70 °C for 10 minutes.
6. 18 µl of each sample was applied to the gel. 2 µl SeeBlue® protein 
standard was also applied to the gel.
7. The gel was run at NuPage gel-program, at 200V for approximately 45 
minutes
3.2.6.2 Using the NuPage® Novex® Bis-Tris Mini SDS Gels, 4-12%
These gels were used  for SDS-PAGE prior to Western blotting and for IVK.
1. The gel was removed from the plastic, and rinsed in deionized water..
2. The comb was pulled out to access the wells, and the white tape at the 
bottom part of the gel was removed. 
3. The wells were washed three times with fresh 1 x NuPage running buffer, 
and the gel mounted in the XCell SureLockTM Mini-cell.
4. The inner chamber was filled with fresh running buffer, and the outer 
chamber filled with running buffer that had been used no more than two 
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times before, but need not be fresh.
5. 18 µl cell lysate for western blotting (see section 3.2.3.3.2) or sepharose 
G beads from Co-ip (see section 3.2.10) was applied to the gel.
6. 2 µl SeeBlue® protein standard, and 2 µl MagicMarkTM protein standard 
were also applied to the gel.
7. The gel was run at NuPage gel-program, at 200V for approximately 45 
minutes.
3.2.7 Western blotting
Western blotting is a method to detect one specific protein/peptide in a 
complex mixture of proteins. The method depends on separation of proteins by 
SDS-PAGE prior to blotting. The protein-bands from the SDS-PAGE are 
transferred onto a solid support, usually a nitrocellulose or nylon membrane by 
electrophoretic transfer, and subsequently subjected to a an antibody specific 
to the protein/peptide in question. This antibody can be enzyme-labeled or 
radio-isotope labeled for visualization. The immunoblotting can also be 
performed indirectly by detecting antigen-antibody complexes by a secondary 
labeled antibody with improved sensitivity. Enzymatic catalyzed methods are 
widely preferred over autoradiography, because it eliminates the need for 
radioactive isotopes, and offers easy detection by chemiluminescence or 
chromogen detection [32].
Protocol:
Prior to blotting, a PVDF (Polyvinylidene fluoride) Immobilon® membrane from 
Millipore®  with a pore size of 45 µm had been washed for 3 seconds in 
methanol, followed by 10 seconds in distilled water, and finally a minimum of 5 
minutes in Blocking buffer.
1. The gel was removed from the XCell SureLockTM Mini-cell, and the wells 
and the «ridge» at the bottom cut off.
2. In a blotting unit, was placed in the following order:
i. 2 blotting pads, soaked in blotting buffer
ii. 2 filter papers, soaked in blotting buffer
iii. The gel
iv. The PVDF-membrane
v. 2 filter papers, soaked in blotting buffer
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vi. 3 or more blotting pads, soaked in blotting buffer (enough to make 
the seal tight).
3. The blotting unit was then placed in the XCell SureLockTM Mini-cell. The 
inner chamber was filled up with fresh blotting buffer, while the outer 
chamber was filled with cold, deionized water. 
4. The Mini-cell was connected to the power supply, and the blot performed 
at NuPage blot program, at 30V for 1 hour.
5. After blotting, the membrane was transferred to a beaker containing PBS 
and washed for 10 minutes on the shaker.
6. Next, the PBS was exchanged for Blocking buffer for 1 hour, still on the 
shaker.
7. After blocking, the membrane was transferred to a 50 ml centrifuge tube, 
and 3 ml blocking buffer + primary antibody in the desired dilution was 
added.
8. The tube was sealed with parafilm, and put on the rotator at slow speed 
at 4 °C o.n.
9. The following day, the primary antibody-Blocking buffer solution was 
removed, and the membrane washed 3 x 5 minutes with PBST.
10. Then secondary antibody diluted in 3 ml PBST was added to the 
membrane, and the tube placed at rotator, slow speed at room 
temperature for 1 hour.
11. After incubation with secondary antibody, the membrane was washed 2 x 
5 minutes with PBST, followed by 2 x 5 minutes wash with Washing 
buffer.
12. After the last wash, 3 ml CDP Star buffer + 6 µl CDP Star was added to 
the tube, and the tube placed at the rotator for 5 minutes.
13. The membrane was removed from the tube, and sealed in plastic.
14. After a few minutes in the dark, the membrane was developed on the 
lumi-Analyst machine.
3.2.8 Transient transfection of Mammalian cells
There are many reasons for artificially introducing DNA into living cells, 
whether it be mutant, or wild-type genetic elements. It can be done in order to 
analyze the characteristics of a specific gene, and its effect on cellular growth 
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and differentiation, or in order to create over-expressing cell lines for 
purification of the product for biochemical characterization or even large-scale 
drug-production [33].
There is a variety of strategies available for delivery of genes into eukaryotic 
cells, all of which fall into one of three categories:
• Transfection by biochemical methods
• Transfection by physical methods
• Virus-mediated transduction
Biochemical methods include calcium-phosphate mediated and 
diethylaminoethyl (DEAE)-dextran mediated transfection in addition to 
liposome-mediated transfection. Physical methods include microinjection and 
electroporation [34]. Virus-mediated transduction is beyond the scope of this 
study.
Transfection can either be made transient or stable, depending on the needs of 
the researcher. In transient transfection, recombinant DNA is introduced into a 
recipient cell-line in order to obtain a temporary, but high level of expression of 
the target gene. The transfected DNA does not usually get integrated into the 
chromosome, and will eventually be lost from the cells through mitosis. This is 
the method of choice when samples are to be analyzed within a short period of 
time. In stable transfection, the target gene is integrated into the chromosomal 
DNA, from where it directs the synthesis of moderate amounts of target 
proteins. This type of transfection is less efficient than transient transfection, 
typically by one to two orders [34].
In this study, cells were transfected by liposome-mediated transfection and 
electroporation, depending on the cell-line being transfected. 
In liposome-mediated transfection, negatively charged phosphate groups on 
DNA binds to the positively charged surface of the liposome, and the residual 
positive charge then presumably mediates binding to negatively charged sialic 
residues on the cell surface. This is, however, a mechanism which is 
incompletely understood [33].
In electroporation, brief electrical pulses create transient pores in the plasma 
membrane, through which DNA can enter the cell [34]. This technique is not 
dependent upon specific characteristics of the cell, and thus can be applied to 
virtually any cell line. The optimal parameters for each cell-line will vary 
however, and need to be optimized in order to obtain efficient transfection[33].
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3.2.8.1 Liposome-mediated transient transfection
3.2.8.1.1 By LipofectamineTM2000
1. The day before transfection, cells were seeded out in 6 well trays (for 
Luciferase assay) or cover-slips (for confocal studies), 250 000 and 15 
000 cells per well respectively.
2. Lipofectamine was combined with OptiMem, and left at room 
temperature for 5 minutes.
Table 13: Reaction volumes for LipofectamineTM2000 transfection
Reagent Luciferase assay Confocal studies
Culturing vessel 6 well plate 8 well cover-slip
LipofectamineTM2000 10 µl 1  µl
Lipofectamine Diluting medium (OptiMem) 250µl 25  µl
DNA 2 µg 0.4 µg
DNA-diluting medium (OptiMem) 250 µl 25  µl
3. In the mean time, DNA was diluted in the same amount of OptiMem as 
the LipofectamineTM2000 .
4. The two solutions were combined, and incubated at room temperature 
for 20 minutes.
5. The medium was removed from the cells by water-suction, and each well 
was supplied with  500 µl or 50 µl OptiMem respectively for 6 well plates 
and 8 well cover-slips.
6. Next, the LipofectamineTM2000 /DNA solution was added to the wells.
7. The cells were put back into the incubator at 37 °C and 5% CO2.
8. After 4 hours, the medium was aspirated off the cells by water-suction, 
and exchanged for fresh, normal growth medium (2 ml and 200 µl 
respectively for 6 well plates and 8 well cover-slips).
9. The cells were out back into the incubator until the following day.
3.2.8.1.2 By Metafectene®Pro
1. 1.5 x 106 HEK293 cells were seeded out in 10 cm plates.
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2. The following day, 1 ml Optimem was mixed with 10 µl Metafectene®Pro 
and 2 µg plasmid DNA, in that particular order of events, and incubated 
at room temperature for 20 minutes.
3. The mixture was added to the plates, and the plates swirled carefully to 
distribute the transfection mixture evenly.
4. The plates were then put back into the incubator until the next day.
5. Cells were harvested according to protocol in section 3.2.3.3.1
3.2.8.2 Transient transfection by electroporation
This technique was applied to transfections of PC12 cells. This is a cell line 
which is hard to transfect by other methods. 
1. 2x 106 PC12 cells were transferred to 15 ml centrifuge tubes, and 
spinned down at 200 rpm for 10 minutes.
2. The medium was carefully removed by water-suction.
3. The cells were then resuspended in 82 µl Nucleofector® solution + 18 µl 
supplement from the Cell Line Nucleofector® kit V + 2 µg plasmid DNA or 
300 nM siRNA.
4. The resulting suspension was next transferred to a Nucleofector® 
cuvette, and electroporated in the Nucleofector® II machine at program 
U 029.
5. 10 µl of the suspension was transferred to each well in an 8 well cover-
slip coated with collagen.
6. The cells were then put back into the incubator until the next day (DNA-
transfection) or for 48 hours (siRNA transfection).
3.2.9 Luciferase assay
Transcriptional activator proteins bind to specific enhancer elements in 
eukaryotic promoters, and stimulate transcription of nearby genes. Separable, 
functional domains of activator proteins confer specific DNA-binding properties. 
These functional domains are remarkably flexible, and readily tolerate fusion to 
heterologous proteins. A popular technique for studying activating and 
regulatory elements of transcriptional activators in mammalian systems 
involves fusion to the DNA-binding domain of the yeast GAL4 protein [35]. By 
co-transfection of such fusion-proteins with a Luciferase-reporter plasmid, 
containing upstream GAL4 activating sequences it is possible to monitor the 
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effect of the (suspected) transcriptional activator protein, without any 
confounding factors, as only fusion proteins containing the yeast GAL4 DNA-
binding domain can bind to the yeast-derived activating sequence. However, it 
is difficult to say whether this protein interacts with the promoter directly, or 
through interaction partners in a pre-initiation complex.
1. From the supernatant of the harvested cells (see section 3.2.3.3.3), 20 
µl of each sample was transferred to a well in a white 96 well plate. Two 
wells were supplied with lysis buffer alone, to serve as reference 
measurements.
2. 100 µl Luciferase buffer was added to each well (reference samples 
included), and the plate covered with aluminum foil to  protect the 
samples from exposure to light.
3. Luciferase activity was measured by a luminometer.
3.2.10 Co-immunoprecipitation
Coprecipitation of proteins from whole-cell extracts is a valuable approach to 
test for physical interactions between proteins of interest. When a precipitating 
antibody is used, the method is referred to as co-immunoprecipitation. 
Coprecipitation techniques can be used to study interactions between known 
proteins, or to identify members of a complex [36].
Before starting, it is important to generate reagents that detect the two 
proteins in the co-precipitate under non-denaturating conditions. If specific 
antibodies for the proteins in question are hard to come by/obtain, the proteins 
can alternatively be tagged with a short peptide or epitope that is recognized 
by commercially available high-affinity monoclonal antibodies. Examples of 
such epitopes are influenza Hemagglutinin protein (HA), human c-Myc and 
FLAG (an epitope specifically designed for use as a tag) [36].
After incubation of the cell extract with the antibody specific for the protein to 
be precipitated (pulled down) or its tag, the cell extract is supplied with 
Sepharose beads conjugated to Protein G or Protein A. These are bacterial 
proteins from Group G Streptococci and Staphylococcus aureus, respectively, 
and both have high affinity for the Fc region of IgG from a variety of species.
The precipitated protein is in this way immobilized on a solid matrix, along with 
any proteins that might be part of a complex with this protein. Through several 
washing steps, other cellular contaminants are removed, and finally the 
precipitated proteins are separated by SDS-PAGE.
By subsequent western blotting with the appropriate antibody, interacting 
proteins may be detected (Figure 6).
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For confirmation of the presence of the precipitated protein, it is advisable to 
strip the WB membrane and re-probe with the antibody directed against this 
protein.
Before starting, Sepharose G beads were washed three times in lysis buffer. 
After the last wash, lysis buffer was added to make a 50% Sepharose G 
solution.
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Figure 6: Flow-chart of co-immunoprecipitation. Ig h and Ig l = 
Immunoglobulin heavy and light chains, NT = no tag. The figure is  
adapted from [36].
1. The supernatant from the harvested cells (see section 3.2.3.3.1) was 
transferred into new eppendorf tubes.
2. 30 µl  of each supernatant was transferred to a new eppendorf tube to 
serve as input control. 8 µl 4x NuPage LDS sample buffer and 2 µl  1M 
DTT was added, and the samples denatured at 70 °C for 10 minutes.
3. To the rest of the supernatant, the appropriate antibody was added in 
the desired dilution, and the tube placed at a rotator, slow speed, at 4 °C 
for 1 hour or o.n.
4. 80 µl  50% Sepharose G beads were added, and the tube returned to the 
rotator for 1 hour.
5. The beads were washed 5 times in 1 ml cold lysis buffer. After the last 
washing step, as much buffer as possible was removed.
6. To the beads, 10 µl  4x NuPage LDS Sample buffer, 2 µl  1M DTT and 8 µl 
distilled H2O was added.
7. The tubes were incubated at 70 °C for 10 minutes, and stored at -20 °C 
until further processing by SDS-PAGE and Western blot (see section 
3.2.6.2 and 3.2.7).
3.2.11 In vitro kinase assay
MAP kinases activate their substrates by transferring a γ-phosphate from ATP to 
a phosphoaccepting residue in the substrate, typically a Serine, Threonine or 
Tyrosine. To investigate potential in vitro substrates for MAP kinases, the two 
proteins are brought together in the presence of radioactively labeled ATP 
under favorable conditions. The samples are subsequently separated by SDS-
PAGE, and visualized on a radiographic plate (IP) containing photostimulable 
storage phosphors. The imaging plate is run through a special laser scanner, or 
CR reader, that reads and digitizes the image. The digital image can then be 
viewed and enhanced using software [37].
Protocol:
1. TBD buffer and kinase buffer (table 1) were prepared fresh for each 
experiment.
2. 20 µl of each protein to be investigated was added to two eppendorf 
tubes. Half of these were to be supplied with premix not containing 
MK5, and the other half with premix supplied with MK5.
3. Premix was prepared for as many samples as needed:
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Table 14: Premix for in vitro kinase assay (per sample)
Reagent Amount
Kinase buffer 4 µl
800 µM ATP 2.5 µl
100 mM DTT 0.8 µl
32p-γ-ATP* 0.3  µl
* 32p-γ-ATP was added in the HOT-lab
4. To half of the premix, 3 µl active MK5 (0.45 µg/ µl) per sample was 
added.
5. The samples were supplied with TBD buffer and premix to reach a total 
volume of 35 µl:
Table 15: Preparation of samples for in vitro kinase assay
Sample Protein TBD buffer Premix
Without MK5 20 µl 7,4 µl 7,6 µl
With MK5 20 µl 5,1 µl 9,9 µl
MK5 only - 25,1 µl 9,9 µl
6. All samples were incubated in a heating block at 30 °C for 1 hour.
7. The reaction was terminated by adding 12 µl 4 x LDS sample buffer + 
1.4 µl 1M DTT to each sample, followed by incubation at 70 °C for 10 
minutes.
8. The samples were run on a NuPage® Novex® Bis-Tris Mini SDS Gel, 4-
12% (SDS-PAGE) for 45 minutes. SeeBlue® protein standard was 
included.
9. After SDS-PAGE, the gel was wrapped in cling-film, and dried in a gel-
drier at 80 °C for 1 hour.
10. The dry gel was placed in a photo-cassette and covered with an Image 
Plate that had been wiped clean by exposure to fluorescent light. The 
plate was left to develop o.n.
11. The following day, the plate was scanned in a FUJI-BAS5000 CR-
scanner, and the picture developed with Image Reader software.
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3.2.12 Immunofluorescent labeling of cells 
Immunocytochemistry is a common laboratory technique that uses antibodies 
to target peptides or proteins in the cell via their specific antigens.
Such studies are easily performed on cultured cells that are grown as 
monolayers. The cells are briefly fixed in low concentrations of 
Paraformaldehyde. What happens next depends on whether the antigen of 
interest is considered to be present at the cell surface or in the cytoplasm. If 
the antigen is present in the cytoplasm, the cells need to be permeabilized. 
This can be done by subjecting them to Triton X-100 or Methanol. Both 
methods work well, but permeabilization by Triton frequently gives a better 
final morphology. After incubation with primary antibody, followed by washing 
steps, a secondary antibody conjugated to a fluorochrome is added. When 
examined under the microscope and exited by a laser of the appropriate 
wavelength, the fluorochrome emits light, and thus reports the location of the 
protein.
1. The cells were fixed by adding 150 µl ice-cold PFA 0.8% to each well in 
a 8 well cover-slip, without removing the growth medium first, followed 
by incubation on ice for 10 minutes.
2. The medium/PFA was removed, and the cells washed carefully with ice-
cold PBS twice.
3. PBS was removed from the cells, and replaced with 150 µl ice-cold 0.1 
% Triton® x-100 in PBS for permeabilization.
4. The cells were incubated on ice for 10 minutes, followed by careful 
washing in ice-cold PBS twice.
5. The PBS was removed, and replaced with 200 µl PBS with 3% goat 
serum, for blocking, for 1 hour at room temperature, with shaking.
6. Primary antibody was added in the appropriate dilution, and the cells 
put on the shaker at room temperature for 1 hour.
7. The cells were washed twice with ice-cold PBS.
8. PBS was removed, and secondary antibody conjugated to a fluorophore 
added in the appropriate dilution.
9. The cells were incubated once more at room temperature, with shaking 
for 1 hour.
10. The cells were washed 4 x 5 minutes with PBS.
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11. To the cells, DraQ5 nuclear stain was added in a 1:1000 dilution, and 
incubated at room temperature for 5 minutes, followed by two times 
wash with PBS.
12. Finally the cover-slip was covered in aluminum foil to protect the 
fluorophores from exposure to light, and kept at 4 °C until investigation 
by confocal microscope.
3.2.13 Site-directed mutagenesis mediated by oligonucleotides
Oligonucleotide-directed mutagenesis is used to add, delete or substitute 
nucleotides in a segment of DNA whose sequence is known. In contrast to 
most other methods of mutagenesis, which typically spawn mixed populations 
of variants, oligonucleotide-mediated mutagenesis specifically generates 
mutations designed by the experimenter. This is achieved by designing and 
synthesizing an oligonucleotide whose sequence contains the desired mutation, 
hybridizing it to a template containing the wild-type sequence, and extending 
the primer with a DNA polymerase harboring proof-reading activity in a 
Polymerase Chain Reaction (PCR) [38].
PCR is a widely used, and highly effective method for in vitro amplification of 
DNA. Through several cycles of rising and lowering temperatures, a heat stable 
DNA polymerase from a thermophilic organism synthesizes new DNA from a 
parental template. The reaction is primed by two artificially made 
oligonucleotides, referred to as primers, and also requires the presence of free 
nucleotides in the reaction mixture. At the beginning of each PCR-cycle, the 
temperature is raised to a level where the double-helix denaturates (the 
strands separate from each other). Then the temperature is slightly decreased 
to a level where the primers anneal to the template. Finally the temperature is 
once more slightly raised to a level where the DNA-polymerase most efficiently 
synthesizes a new DNA strand. Then the cycle is repeated several times, 
creating an exponentially growing number of DNA-strands.
Table 16: Premix for site-directed mutagenesis (per sample)
Reagent Amount (µl)
dH2O 39.6
10 x Pfu buffer 5
Primer 1 (100 ng / µl) 1.3
Primer 2 (100 ng / µl) 1.3
12.5 mM dNTP 0.8
Pfu Turbo enzyme 1
Total: 49
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The premix was transferred into an eppendorf tube, and 1 µl plasmid DNA (25 
ng/µl) was added.
In this experiment, a graded PCR was used, to investigate the optimal 
annealing temperature of the primers
Table 17: PCR conditions for site-directed mutagenesis
95 °C 30 seconds
Gradient 50 °C – 70 °C 30 seconds
68 °C 7 minutes
Cycles 14
After the PCR reaction 1 µl DpnI was added to each sample, and the samples 
incubated at 37 °C  for 1 hour. This was done in order to remove the template 
which was not mutated, but methylated. The DNA generated during PCR will 
contain the mutation, but is not methylated. DpnI cuts the sequence GATC 
when A is methylated. In this way, unmutated DNA is destroyed.
3.2.14 Cloning using restriction endonucleases
Restriction endonucleases recognize short DNA sequences and cleave double-
stranded DNA at specific sites within or adjacent to these recognition sites 
[28]. Most plasmid vectors contain several restriction sites for easy cloning of 
genetic elements. These restriction sites are often contained within a 
geographically constricted part of the vector called a multiple cloning site or 
polylinker. Before cloning a genetic element from one vector into another, it is 
necessary to investigate the polylinkers of each vector, to decide whether they 
contain compatible restriction sites. If not, restriction sites may be introduced 
by site directed mutagenesis. After cutting with restriction endonucleases, the 
fragmets are separated on an Agarose gel. The desired fragments are cut out 
of the gel, and the DNA retrieved by centrifugation of the gel through a 
column. Finally, the fragments are joined together by DNA-ligase. The ligated 
fragments are then transformed into competent bacteria, which produce large 
amounts of the clone. The cloned DNA can then be purified and sequenced to 
verify that the desired fragment has been cloned into the recipient vector in 
the correct reading-frame and orientation.
Protocol:
1. All reagents were mixed, and the samples incubated at 37 °C for 2 hours 
or overnight. In this study, the recipient vectors were pENTR1A and 
pENTR3C (table 3).
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Table 18: Reaction set-up for cutting of dsDNA with restriction endonucleases
Sample 1 2
Buffer* 2 µl 2 µl
Donor vector 1 µg
Recipient vector 1 µg
Restriction endonuclease 1 1 µl 1 µl
Restriction endonuclease 2 1 µl 1 µl
BSA 0.7  µl 0.7  µl
ddH2O To 20 µl To 20 µl
2. The resulting fragments were next run on a 1% Agarose gel, and the 
desired fragments cut out of the gel.
3. The DNA was retrieved by spinning the gel-fragment through a custom-
made column, consisting of eppendorf tubes and filter papers.
4. The two DNA-fragments were then joined together by DNA-ligase in the 
following reaction:
Table 19: Ligation reaction
Reagent Amount
T4 ligation buffer 2 µl
T4 DNA ligase 1 µl
Donor fragment X µl*
Recipient fragment 1-2 µl
ddH2O To 20 µl
* Several samples were made for each reaction, each with different amounts of donor 
fragment (in the range 7- 16 µl)
5. The samples were incubated at 16 °C o.n. before transformation into 
competent DH5 cells, followed by sequencing.
3.2.15 Gateway® cloning
The Gateway® system for easy cloning is developed by Invitrogen. In principle, 
the system is based on cloning the DNA sequence of interest into the multiple 
cloning site of an  ENTRY vector, using restriction endonucleases and DNA 
ligase, thereby creating an ENTRY clone. The ENTRY vector contains attL1 and 
attL2 sites for specific recombination with a Gateway destination vector, so that 
the ENTRY clone can easily be cloned into a variety of destination vectors, 
displaying different features, thereby creating different expression clones. The 
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destination vectors also contain dual selection markers, to ensure that only 
bacteria carrying clones in which the DNA sequence has been inserted 
correctly, will propagate. This eliminates the need for subsequent sequencing 
reactions, and ensures consistent results throughout the experiment. The 
recombination between ENTRY clones and destination vectors is achieved by 
using pre-made enzyme mixes, containing buffers and enzymes, and is 
performed in a one hour, room temperature reaction.[29]
Protocol:
1. The following components were added to an eppendorf tube:
Table 20: Reaction set-up for Gateway® cloning
Reagent Amount
ENTRY clone (50-150 ng) 1-7  µl
Destination vector (150 ng/µl) 1 µl
TE buffer, pH 8.0 To 8  µl
2. The LR clonase® II enzyme mix was thawed on ice, and vortexed briefly 
x 2.
3. To each sample, 1 µl* LR clonase® II enzyme mix was added, and the 
contents mixed well by vortexing briefly x 2.
4. The samples were incubated at 25 °C for two hours.
5. Then, 1 µl Proteinase K solution was added to each sample to terminate 
the reaction. The samples were vortexed briefly, and incubated at 37 °C 
for 10 minutes.
6. The cloned DNA was further transformed into competent DH5α cells by 
the procedure in section 3.2.16.
* The original protocol from Invitrogen states 2 µl, but in order to reduce costs, it was 
decided upon using only half the amount LR clonase® II enzyme mix, and double the 
incubation time from one to two hours.
3.2.16 Transformation of competent bacteria
Bacteria that are able to take up naked DNA directly from their environment, 
are said to be competent. Some bacteria are naturally competent, and those 
that are not, can be made competent artificially, either by treatment with Ca 
Cl2 or by electroporation.
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The process of introducing DNA into competent cells is called transformation. 
In CaCl2 treated cells this is achieved by briefly heat-shocking a mixture of cells 
and DNA, and for cells made competent by electroporation, the transformation 
is executed by mixing DNA with the bacterial cells as they are elctroporated. 
Electroporation creates transient pores in the cell membrane, through which 
The DNA can enter the cells.
In this study, CaCl2 treated competent cells were used for transformation.
Protocol:
1. Competent cells were collected from the nitrogen tank, and thawed on 
ice.
2. To 200 µl competent cells, approximately 20 ng* plasmid DNA was 
added.
3. The mixture of cells and DNA was incubated on ice for 30 minutes.
4. The cells were then heat-shocked at 42 °C for 90 seconds, followed by 
incubation on ice for another 90 seconds.
5. 800 µl SOC medium was added, and the cells put in the incubator at 37 
°C with horizontal shaking for 45 minutes.
6. The cells were plated out on LB-plates containing the appropriate 
selective antibiotic, as specified by the plasmid in question.
7. The plates were incubated at 37 °C overnight.
* For transformation of ligation-products (section 3.2.14) the amount was variable.
3.2.17 DNA sequencing 
When clones have been made and purified, they need to be verified by 
sequencing of the DNA. To achieve this, the DNA is combined with a mixture 
containing a Taq-polymerase, unlabeled dNTPs and ddNTPs that are labeled 
with fluorescent dyes, one specific color for each ddNTP (A, T, G, C). The ratio 
of dNTPs vs ddNTPs is approximately 100:1. One such mixture is Big Dye 3.1. 
Specific primers for the DNA are also included. The samples are next subjected 
to a PCR reaction, and the DNA amplified much the same way as described 
earlier. The ddNTPs lack a 3' hydroxyl end to which the next nucleotide can 
attach. Thus, each time a ddNTP is incorporated into the growing strand, the 
reaction terminates, resulting in a myriad of DNA fragments of different 
lengths, each ending with a specific ddNTP as ordinated by the DNA template. 
When the run has ended, the fragments are separated on a gel, and the 
fluorescent dyes that are attached to the ddNTPs exited by a UV laser [30]. An 
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automatic scanner then“reads” the gel, shortest fragment first, followed by the 
one which is one nucleotide longer and so on, ascribing A, T, G or C as directed 
by the color of the dye.
Protocol:
1. The following premix was made:
Table 21: Premix for DNA sequencing
Reagent Amount
5 x sequencing buffer 3 µl
Big Dye 3.1 0.5 µl
pENTR 5' primer 1 µl
2. To the premix, 500 ng plasmid DNA was added.
3. The samples were run at the following program:
Table 22: PCR conditions for sequencing PCR
96 °C 10 seconds
50 °C 5 seconds
60 °C 4 minutes
Cycles: 30
4. The samples were delivered to the sequencing lab/facility at 
Universitetssykehuset i Nord-Norge (UNN) where the electrophoresis and 
scan was performed on a 3130xl Genetic Analyzer from Applied 
biosystems/HITACHI.
3.2.18 FRET-studies
Förster resonance energy transfer, also called fluorescence resonance energy 
transfer or FRET for short, is a technique that allows establishment of 
molecular interactions that would otherwise be beyond the resolution of a light 
microscope. FRET occurs when two fluorochromes, which are closely associated 
with each other, can interact such that the light used to excite one will be 
transferred as internal energy to the other fluorochrome, and then emitted as 
longer wavelength light characteristic of the second fluorochrome. For FRET to 
occur, the fluorescence emission from the first fluorophore, the donor, must 
overlap with excitation spectrum of the second fluorophore, the acceptor, and 
the molecules must be within a distance of 2-6 nm of each other [31].
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Protocol:
1. 15 000 HeLa cells were seeded out in a cover-slip, and transfected by 
Lipofectamine according to the procedure in section 3.2.8.1.1
2. The following day, the cells were fixed by adding 150 µl ice-cold 0.8% 
PFA and incubating on ice for 10 minutes.




Studies by our group had shown that HSP27 is a bona fide substrate for MK5 
[15]. This prompted us to examine whether other heat shock proteins could be 
targets for MK5. Sergiy Kostenko in our group showed that the HSP40 member 
DNAJB1 could also be phosphorylated by MK5 in vitro (Figure 7). 
To investigate DNAJB1 as a possible substrate of MK5, the two proteins were 
included in further in vitro kinase assays, co-localization studies and interaction 
studies (Co-ip and FRET).
4.1  MK5 and DNAJB1 co-localize in the cell
The original finding that MK5 could phosphorylate HSP40 suggests that there is 
a physical interaction between these two proteins. To test this, we first set out 
to study the subcellular localization of both proteins. Fluorescently tagged MK5 
and DNAJB1 proteins were ectopically expressed in HeLa and PC12 cells and 
their localization was visualized by confocal microscopy studies. As shown in 
Figure 8, 9 and 10, both proteins localize mainly to the nucleus in both cell 
lines. HSF1 was also included in some of these studies, and it seems that this 
protein is also localized mainly within the nucleus (Figure 8 and 11).
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Figure 7: In vitro kinase performed on various heat shock proteins  
in the presence of active MK5. Lane A: HSP90 + MK5. Lane B: 
HSP90. Lane C: HSP70 + MK5. Lane D: HSP70. Lane E: 
HSP40/DNAJB1 + MK5. Lane F. HSP40/DNAJB1. Lane G: HSP27 + 
MK5. Lane H: HSP27. Lane I: MK5. Lane J: HSP27 + PKD 
(included as a positive control for phosphorylation of HSP27).  
Phosphorylation of DNAJB1 is indicated by an arrow. [Kostenko 
unpublished results].
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Figure 8: HeLa cells co-transfected with ECFP-DNAJB1, EYFP-MK5 and Cherry-HSF1. A: only  
ECFP-DNAJB1 shown. B: only EYFP-MK5 shown. C: only Cherry-HSF1 shown. D: Pictures A-C 
merged.
Figure 9: PC12 cells. A: transfected with ECFP-DNAJB1. B: 
Transfected with EYFP-MK5.
Figure 10: PC12 cells co-transfected with ECFP-DNAJB1 and EYFP-MK5. A: only ECFP-DNAJB1 
shown. B: only EYFP-MK5 shown. C: Pictures A and B merged.
As seen in Figure 11, Co-transfection of DNAJB1 and HSF1 with the 
constitutively active MK5L337A did not seem to alter the pattern of subcellular 
localization  of either protein.
Forskolin treatment of MK5 led to nucleocytoplasmic redistribution, as expected 
[13][14], while it did not seem to alter the subcellular distribution of DNAJB1 
(Figure 12). Forskolin is a diterpene that raises the level of cAMP in the cell, 
thus activating the cAMP/PKA pathway. These results therefore indicate that 
activation of MK5 by the cAMP/PKA pathway does not influence subcellular 
distribution of DNAJB1.
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Figure 11: HeLa cells co-transfected with ECFP-DNAJB1, EYFP-MK5L337A and Cherry-HSF1. A:  
only ECFP-DNAJB1 shown. B: only EYFP-MK5L337A shown. C. only Cherry-HSF1 shown. D: 
Pictures A-C merged.
Figure 12: HeLa cells transfected with ECFP-DNAJB1 and EYFP-MK5. With and 
without Forskolin treatment.
Co-expression of ECFP-DNAJB1 and EYFP-MK5 did not seem to alter the 
localization of either protein upon Forskolin treatment (Figure 13). One would 
normally expect EYFP-MK5 to re-localize to the nucleus, and could, as such, 
speculate that interaction with ectopically expressed DNAJB1 retained the 
protein in the nucleus. Previous experience with MK5 in HeLa cells, however, 
has shown that MK5 does not always relocate to the cytoplasm upon forskolin 
treatment [Kostenko unpublished results], and, based on this experience it 
would be unwise to conclude that the lack of nucleocytoplasmic redistribution 
of MK5 is due to the presence of DNAJB1.
4.2 MK5 and DNAJB1 exist in complexes.
If DNAJB1 is indeed a substrate for MK5, the two proteins must at some point 
engage in physical interaction. This interaction, if existent, can be transient as 
an enzyme-substrate complex, and, as such, difficult to capture. In an attempt 
to monitor such interaction, FRET-studies and co-immunoprecipitation of MK5 
and DNAJB1 were performed.
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Figure 13: HeLa cells co-transfected with ECFP-DNAJB1 and EYFP-MK5. With and without 
Forskolin treatment.
4.2.1 FRET-analysis indicates physical interaction between MK5 
and DNAJB1.
HeLa cells were co-transfected with pDest-ECFP-MK5 and pDest-EYFP-DNAJB1 
or pDest-EYFP-CREB. CREB has previously proven to have no interaction with 
MK5 [14], and as such functioned as a negative control. Details on the 
construction of the pENTR3C-CREB vector that was used to make EYFP-CREB 
are supplied in appendix C. The cells were analyzed by confocal microscope.
The data from the FRET-study indicate that FRET occurs between CFP-MK5 and 
YFP-DNAJB1, corresponding to a physical proximity of the two fluorophores 
between 2 and 6 nm, indicating a molecular interaction (Figure 14). Between 
pDestECFP-MK5 and the negative control pDestEYFP-CREB, no energy transfer 
was observed after photobleaching (results not shown).
4.2.2 Co-immunoprecipitation
To further establish evidence of an interaction between MK5 and DNAJB1, co-
immunoprecipitation was applied. In the first attempt, EGFP-tagged MK5 and 
3xFLAG-tagged DNAJB1 were co-transfected into HEK293 cells. Several 
repetitions were made to optimize dilution of the antibodies.
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Figure 14: Result of FRET study. CFP and YFP emission signals were captured before and after  









EGFP-MK5 is a fusion protein of approximately 81 kDa (27+54). As seen in 
Figure 15, it appears EGFP-MK5 is present in immunoprecipitates of full length 
DNAJB1 (HSP40) and DNAJB1 J-domain, but absent in immunoprecipitates of 
the empty control vector, indicating interaction between both MK5 and full 
length DNAJB1 and MK5 and DNAJB1 J-domain. HSF1 was also included in this 
experiment, and  similar to DNAJB1, there seemed to be an interaction with 
MK5.
Because of the fact that the light chain of the antibody has a molecular mass of 
approximately 25 kDa, and GFP has a molecular mass of approximately 27 
kDa, questions can be raised as to whether the band seen in the samples 
containing the empty EGFP vector is antibody light chain or GFP. This further 
leads to the speculation that the immunoprecipitation of EGFP-MK5 might be 
due to interactions between DNAJB1 and the GFP-part of the fusion protein 
rather than between DNAJB1 and MK5.
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Figure 15: Upper panel: Co-ip performed in HEK293 cells co-transfected with DNAJB1 and 
MK5, DNAJB1 J-domain and MK5 and HSF1 and MK5. EGFP-C1 served as empty control.  
Lower panel: The membrane in the upper panel stripped and re-probed with anti FLAG in  
WB.
To avoid the possible confusion of GFP with the light chains of the antibody, 
EGFP-tag was substituted with HA-tag. This approach soon presented us with a 
problem. The signals reported by the antibody from the co-immunoprecipitates 
were a lot stronger than the signals reported from the input controls (Figure 
16). By idea, the amount of HA-MK5 should be higher in the input controls 
than in the co-immunoprecipitates, and as such, should report a stronger 
signal when probed with the anti HA antibody. In addition, the band 
corresponding to the size of HA-MK5 seemed to be present in both 
immunoprecipitates containing DNAJB1 and not containing DNAJB1; indicating 
that if there was indeed an interaction, it most probably was between HA-MK5 
and the FLAG-tag. However, the size of HA-MK5 (~55 kDa) is quite close to the 
size of the heavy chain of the antibody (~50 kDa) and therefore the bands 
appearing close to 50 kDa might also be the IgG heavy chain. Several 
attempts, and dilutions of the anti HA antibody, did not change the outcome of 
the co-ip. Finally it was decided to substitute anti HA for anti MK5 in the WB.
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Figure 16: Co-immunoprecipitation of DNAJB1 and MK5 performed in HEK293 cells.  A: Co-ip  
and input controls. Immunoprecipitation performed with anti FLAG, WB performed with anti  
HA. B: Same Co-ip as A, performed on another blot. C: Membrane A stripped and re-probed 
with anti FLAG. FLAG alone is too small to be visualized on the blot.
As seen in Figure 17, substitution of anti HA with anti MK5 in the western 
blotting did not lead to any dramatic changes in the outcome of the co-ip, 
apart from the fact that signals from the input controls now appeared to be of 
equal strength as the signals reported from the immunoprecipitates. Still, a 
band close to 50 kDa appeared in both immunoprecipitates containing DNAJB1 
and not containing DNAJB1, indicating, once more, that there might be 
interaction between HA-MK5 and the FLAG-tag, or that it is actually the heavy 
chain of the antibody that is detected. Additionally, endogenous co-ip turned 
out negative, suggesting that there is no interaction between MK5 and 
DNAJB1. Based on the co-ip experiments, it remains inconclusive whether MK5 
and DNAJB1 interact directly with one another in a stable complex.
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Figure 17: Three different Co-ip performed in HEK293 cells. A: Co-ip and input 
controls. Immunoprecipitation performed with anti FLAG and Western blotting with  
anti MK5. B: Two different Co-ip performed on the same blot. Same procedure as in  
A. In the Co-ip to the right, the  empty lane is endogenous cell suspension,  
immunoprecipitation was performed with anti HSP40.
4.3 MK5 phosphorylates DNAJB1 in vitro.
Previous findings showed that MK5 can phosphorylate DNAJB1 in vitro. We 
wanted to identify possible phosphoacceptor sites. To narrow down the search, 
the protein was separated into its individual domains [Kostenko unpublished 
results]. For details on the construction of these domains, see appendix A. 
All domains were included in an in vitro kinase assay. Prior to the kinase assay, 
all recombinant proteins/protein-domains needed to be purified. This was 
achieved by cloning their coding sequence from the ENTRY vector in which they 
resided into the pDESTTM15 vector (table 3) by the Gateway® technology. The 
pDESTTM15 vector contains a GST-tag for the construction of GST-fusion 
proteins, and an IPTG-inducible promoter for high expression levels of the 
fusion protein [39]. The approximate molecular mass of each fusion-protein is 
given in table 23.
Table 23: Approximate molecular mass of DNAJB1 fusion proteins
Fusion-protein Approximate molecular 
mass (kDa)
GST-DNAJB1, full length 64
GST-DNAJB1 J-domain 34
GST-DNAJB1 G/F-rich domain 30
GST-DNAJB1 Proximal part of C-terminal 
domain (aa 106-175)
34
GST-DNAJB1 Central part of C-terminal domain 
(aa 176-245)
34




Figure 18: Schematic illustration of  full length DNAJB1 protein, individual  
domains and three single mutations in the proximal part  of the C-terminal  
domain as constructed by Sergiy Kostenko [Kostenko unpublished results].
The first in vitro kinase assay indicated phosphorylation of J-domain and the 
proximal part of C-terminal domain (see Figure 20 below). 
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Figure 20: In vitro kinase assay performed on full length DNAJB1 and its individual domains in 
the presence of  active MK5. Phosphorylation of J-domain and proximal part of C-terminal is  
indicated by arrows.
Figure 19: Result of GST-fusion protein purification using Thrombin as  
eluting agent. Protein standard in the far left lane is SeeBlue®. Lane A:  Full 
length DNAJB1. Lane B: J-domain. Lane C: G/F-rich domain. Lane D: 
Proximal part of C-terminal. Lane E: Central part of C-terminal. Lane F: 
Distal part of C-terminal. The band corresponding to the protein of interest  
is circled in each lane. The proteins were stained by Coomassie Brilliant  
Blue.
Based on these results, the sequences of the two domains were investigated 
for possible phosphoacceptor sites using an online phosphorylation prediction 
algorithm, NetPhos 2.0 [40]. Two putative phosphoacceptor sites were 
predicted for the J-domain, and three for the proximal part of the C-terminal 
domain (Figure 21).
As seen in the figure, there were two other possible phosphosites within the J-
domain that reported signals above the threshold (one Threonine and one 
Serine), but compared to the other two sites, the signals reported were 
relatively low. We therefore decided to first concentrate on investigating the 
phosphoacceptor potential of the other two. Detailed information about the 
results of the phosphosite prediction is given in appendix E.
According to the results of the phosphorylation site prediction, primers were 
designed to create mutations that would leave the putative phosphosites inert 
to phosphorylation by kinases. This was achieved by substituting a Serine (S) 
or a Tyrosine (Y) with an unphosphorylatable Alanine (A) by site-directed 
mutagenesis. The following mutants were generated: in the J-domain: Y6A and 
S16A, and in the proximal part of C-terminal (amino acid 106-175): S149A, 
S151A and S171A [Kostenko, unpublished results] For further details on 
construction of the mutants, see appendix B.
In vitro kinase assay was performed with the three mutants of the proximal 
part of the C-terminal domain of DNAJB1.
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Figure 21: Result of phosphorylation site prediction in DNAJB1 using the NetPhos 2.0 
phosphorylation prediction algorithm. Two putative phosphosites within the J-domain are  
circled to the far left in the diagram, and three putative phosphosites within proximal part  
of C-terminal domain (aa 106-175) are circled in the middle of the diagram. The circled  
peaks represent the phosphosites that were chosen to be investigated further by site  
directed mutagenesis and IVK .
As seen in Figure 22, all three mutants in the proximal part of the C-terminal 
domain still became phosphorylated, though signals of lower intensity were 
detected for each of them than for the wild-type domain. The observed 
residual phosphorylation of the single mutants was possibly due to 
phosphorylation of the two other phosphosites that were still present in each 
mutant. Based on this assumption, it was decided to create a triple mutant for 
the proximal part of C-terminal domain. This was done by designing a primer 
containing a double mutation for S149A and S151A, and performing site-
directed mutagenesis on the template already carrying the S171A mutation. 
Information about primers and reaction conditions is given in tables 6, 15 and 
16 and section 2.2.13. When sequenced, quite remarkably, some of the 
samples contained the desired mutation, but the original mutation (S171A) 
seemed to have reverted (Figure 23). No samples contained all three 
mutations. 
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Figure 22: In vitro kinase assay on full length DNAJB1, individual domains and single mutants  
in the proximal part of C-terminal domain in the presence of active MK5. Phosphorylation of J-
domain, proximal part of C-terminal and single mutants is indicated by arrows.
Based on this result, a new strategy for construction of the triple mutant was 
devised. The recombinant DNA carrying the double mutation (see Figure 23) 
was used as template for site-directed mutagenesis by the S171A primer, and, 
as seen in Figure 24, this time the mutagenesis was successful.
After the search for possible phosphoacceptor sites within the J-domain and 
the proximal part of C-terminal had been initiated, the first IVK assay including 
all domains was repeated (Figure 25). In addition to phosphorylation of J-
domain and proximal part of C-terminal, phosphorylation of G/F-rich domain 
was observed. A band also appeared in the distal part of C-terminal (aa 239-
341), but this band was of a size too small to correspond to this domain. It 
might be Thrombin, which was used for protein purification, and has a 
molecular mass of approximately 36 kDa, but the band seems to be too small, 
and if it was indeed Thrombin, the band should be present in all samples.
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Figure 23: Result of site directed mutagenesis performed on DNAJB1 S171A with the  
S149A_S151A primers. The Incorporated forward primer is shown in red. Nucleotide triplets  
causing the change from amino acid Serine to Alanine are highlighted in yellow. The reverted 
mutation, S171A, is circled in black.
Figure 24: Result of site-directed mutagenesis performed on DNAJB1 S149A_S151A with the 
S171A primers. The incorporated forward primer is shown in red. The nucleotide triplet  
causing the change from amino acid Serine to Alanine is highligthed in yellow. The pre-existing 
mutations, S149A and S151A are shown i blue fonts.
Before the new mutants were included in an in vitro kinase assay, it was 
discovered that the pDESTTM15 vector did in fact not contain a Thrombin 
cleavage-site, like previously assumed. GST-fusion protein purification of 
proteins expressed from the pDESTTM15 vector had so far been executed 
according to the protocol for Thrombin elution. Without a Thrombin cleavage 
site present, the low protein yield from previous purification-attempts could 
easily be explained. As a consequence of this discovery, the full length protein, 
all domains and all mutants were purified once more, this time by the protocol 
for Glutathione elution. The results are given in Figure 26 and 27.
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Figure 25: In vitro kinase assay performed on full length DNAJB1 + its individual domains in  
the presence of active MK5. Concentration of G/F-rich domain is increased while the rest of the  
procedure is identical to the one seen in in Figure 20.
Figure 26: GST-fusion protein purification using Glutathione as eluting agent.  
1: Y6A first eluate, 2: Y6A second eluate, 3: S16A first eluate, 4: S16A second 
eluate, 5: S149A_S151A first eluate, 6: S149A_S151A second eluate, 7: 
S149A_S151A_S171A first eluate, 8: S149A_S151A_S171A second eluate. SB:  
SeeBlue® protein standard.
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From figure 26 and 27 it is apparent that the yield of protein from the GST-
fusion protein purification is quite variable. The yield of full length DNAJB1, the 
G/F-rich domain, the central part of C-terminal and the distal part of C-
terminal is considerably lower than for the other domains and the mutants. 
The sample containing the G/F rich domain even seems completely devoid of 
protein. We also see that even though the desired proteins are enriched, most 
of the samples also contain contaminants, some more than others.
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Figure 27: GST-fusion protein purification using Glutathione as eluting agent.  1: 
DNAJB1, 2: J-domain, 3: G/F-rich domain, 4: Proximal part of C-terminal (aa 106 -  
175), 5: Central part of C-terminal (aa 176 - 245), 6: Distal part of C-terminal (aa 
239- 341), 7: S149A, 8: S151A, 9: S171A. SB: SeeBlue® protein standard.
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In vitro kinase assay was performed on full length protein, all domains and all 
mutants, including the two J-domain mutants (Y6A and S16A).
The results from the IVK on full length protein and individual domains are not 
shown due to technical difficulties. However, it seemed that the J-domain, the 
proximal part of C-terminal and the G/F-rich domain were not the only 
domains of DNAJB1 to be phosphorylated by MK5 in vitro. Both the central and 
the distal part of C-terminal were also phosphorylated in this assay. This is in 
accordance with the results of the phosphorylation site prediction (see Figure 
21) From the figure it is apparent that several putative phosphorylation sites 
are present in the two other domains. 
It also seems that both Serine 149, Serine 151 and Serine 171 are 
phosphorylated by MK5 in vitro (Figure 28). Because of the fact that 
phosphorylation is not completely abolished in the triple mutant, it is plausible 
to assume there might be additional phosphoacceptor sites within the proximal 
part of the C-terminal region, although this is not reported by the 
phosphorylation site prediction algorithm that was used. Phosphorylation of J-
domain carrying the Y6A mutation seems to be slightly weaker than for the 
wild-type J-domain, whilst the S16A mutation does not seem to influence 
phosphorylation of this domain. Taken together, these results indicate that in 
addition to Tyrosine 6, Serine 149, Serine 151, and Serine 171, DNAJB1 
possesses additional MK5 phosphoacceptor sites, at least in vitro.
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Figure 28: In vitro kinase assay performed on full length DNAJB1 protein, J-domain, proximal  
part of C-terminal and mutants Y6A, S16A, S149A_S151A and S149A_S151A_S171A in the 
presence of active MK5. Relevant phosphorylation is indicated by arrows.
4.4 DNAJB1 inhibits MK5 activity
DNAJB1 has previously been shown to inhibit the transcriptional activity of 
HSF1 in COS-7 cells [23]. These cells express SV40 large T-antigen, a protein 
that similar to DNAJB1, contains a J-domain [41]. We wanted to repeat this 
experiment in HEK293 cells as these cells do not express viral proteins with a 
J-domain. To achieve this, Luciferase assays including GAL4-HSF1 and DNAJB1 
or empty control vector were conducted. In both transfections, the reporter 
plasmid GAL4-E1b-Luc was also included.
From figure 29 we can see that the trend seems to be that DNAJB1 
downregulates HSF1-mediated transcription. This was expected based on the 
earlier findings of Shi et al. [23]. The significance of the difference between 
cells transfected with DNAJB1 and cells transfected with empty control vector is 
different for cells treated with 1 µg DNA and 2.5 µg DNA. This is most likely 
due to the high standard deviation observed in the former data-set.
We also wanted to see if MK5 had any impact on the expression or 
transcriptional activity of HSF1. Thereto, Luciferase assays including GAL4-
HSF1 and MK5 or empty control vector were conducted. In both transfections, 
the reporter plasmid GAL4-E1b-Luc was also included.
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Figure 29: Luciferase assay of HEK293 cells transfected with pGAL4-HSF1 and pcDNA3 or  
pGAL4-HSF1 and pFLAG-DNAJB1, 1 µg and 2.5 µg respectively. Three parallels were made  
for each transfection. An unpaired t-test showed that the difference between the first two 
data-sets was not significant (p= 0.3479). For the second data-set, the difference was  
significant (p= 0.0289).
From Figure 30 it seems that MK5 has a slightly stimulating effect on HSF1, 
but the difference between cells transfected with MK5 and empty vector is too 
small to be significant. Therefore, the effect of MK5 on HSF1 remains 
inconclusive.
Since the main focus in this study is on the interaction between MK5 and 
DNAJB1, we wanted to investigate whether DNAJB1 had a regulatory effect on 
MK5. HEK293 cells were co-transfected with pDest3xFLAG-DNAJB1 + pM-MK5 
and pDest3xFLAG (empty vector)+pM-MK5. In both transfections, the reporter 
plasmid GAL4-E1b-Luc was also included. The pM-MK5 plasmid encodes a 
fusion protein containing the DNA binding domain of GAL4 and MK5. This 
fusion protein will therefore bind to the GAL4 binding sites of the GAL4-E1b-
LUC reporter plasmid and affect transcription of the Luciferase gene from the 
E1b promoter.
78
Figure 30: Luciferase assay of HEK293 cells transfected with pGAL4-HSF1 and pEGFP or  
pGAL4-HSF1 and pEGFP-MK5, 1 µg and 2.5 µg respectively. Three parallels were made for  
each transfection.  An unpaired t-test showed that the difference between the data-sets was  
not significant (p= 0.2851 and 0.2813 respectively).
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Figure 31: Luciferase assay of HEK293 cells transfected with either pM-MK5 
+ pDest 3 xFLAG-HSP40 or pM-MK5 + pDest3xFLAG. Three parallels were  
made for each transfection. An unpaired t-test showed that the difference 
between the data-sets was significant (p = 0.0149)
Figure 32: Luciferase assay of HEK293 cells transfected with either pM-
MK5 + pDest 3 xFLAG-HSP40 or pM-MK5 + pDest3xFLAG. Three parallels  
were made for each transfection. An unpaired t-test showed that the  
difference between the data-sets was significant (p= 0.0002)
From Figure 31 and 32 it appears that DNAJB1 does indeed 
inhibit/downregulate MK5 in some manner, but what property remains 
unknown.
4.5 DNAJB1 seems to be involved in β-tubulin rearrangement 
through the cAMP/PKA pathway.
It has earlier been shown that MK5 is involved in F-actin rearrangement 
through HSP27 [15], and quite recently it was demonstrated that DNAJB6 
large splice variant, a close relative of DNAJB1, can lead to morphological 
changes in cells through inhibition of Wnt/β-catenin signaling, thereby 
restricting malignant behavior [42]. On the basis of this, we decided to 
investigate whether DNAJB1 could be involved in rearrangement of any other 
structural proteins. 
DNAJB1 was knocked down in PC12 cells by 300nM siRNA (Figure 33) 
From Figure 33 we see that transfection with 300 nM siRNA directed against 
DNAJB1 leads to drastically reduced levels of DNAJB1 in PC12 cells, although 
expression is not completely abolished. 
New cells were transfected with siRNA and stained for β-tubulin (see table 4 
and section 3.2.12).
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Figure 33: Western blot of PC12 cells using anti HSP40 antibody. Lane A: transfected 
with 50 nM siRNA directed against DNAJB1. Lane B: transfected with 100 nM siRNA 
directed against DNAJB1. Lane C: transfected with 300 nM siRNA directed against  
DNAJB1. Lane D: untransfected cells. mm: MagicMarkTM protein standard. The cells  
were harvested 48 hours post-transfection. 
As is not necessarily apparent from Figure 34, the overall impression was that 
β-tubulin rearrangement, as observed in mock-transfected cells after forskolin 
treatment, was not present in cells where DNAJB1 was knocked down by 
siRNA.
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Figure 34: PC12 cells stained for β-tubulin isotype III. A: Mock 
nucleofector transfection, untreated. B: Mock Nucleofector transfection,  
treated with Forskolin for 30 minutes. C: Transfected with 300 nM siRNA 
directed against DNAJB1, untreated. D: Transfected with 300 nM siRNA 
directed against DNAJB1, treated with forskolin for 30 minutes.
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5 Discussion
In this study we have shown that DNAJB1 is a novel substrate for MK5. Both 
proteins co-localize and interact with each other in the cell, at least when 
ectopically expressed. Additionally, MK5 can phosphorylate DNAJB1 at several 
sites in vitro. Studies aimed at elucidating the functional importance of this 
interaction were initiated.  
Co-localization studies revealed co-localization of ectopically expressed DNAJB1 
and MK5, mainly within the nucleus. Previous studies have shown that in 
unstressed cells, DNAJB1 is localized faintly throughout the cell, and that upon 
heat-shock it accumulates in nuclei and nucleoli [43]. Ectopically expressed 
MK5 has been shown to mainly localize to the nucleus. From figure 9 and 12 it 
seems that DNAJB1 also localizes mainly to the nucleus in cells that are not co-
transfected with MK5. This suggests that nuclear localization of DNAJB1 is not 
dependent upon co-expression of MK5, but could be due to a state of stress in 
the cell induced by transfection or simply the fact that the protein is over-
expressed. Several attempts at immunofluorescence staining of the 
endogenous proteins were made, but none were unequivocally conclusive, 
most likely due to poor antibody quality. 
Co-immunoprecipitation did not give any unambiguous answers to the question 
of interaction between MK5 and DNAJB1. Co-ip is a widely used method that 
allows the detection of protein-protein complexes in cells. However, one 
limitation is that often the two proteins of interest are ectopically over-
expressed, which may lead to non-physiological concentrations and misplacing 
of the proteins in the cell. Therefore, if possible, co-immunoprecipitation of the 
endogenous proteins should be performed. Both approaches were performed 
on MK5 and DNAJB1, and interaction was only reported in co-ip where the 
proteins were ectopically over-expressed, and not in the endogenous 
precipitate.
Another drawback of the method is that it does not guarantee that the two 
proteins interact directly. Interaction can be through a third, or possibly even 
more proteins as part of a complex. To solve this problem, a GST pull-down 
can be performed. This is an in vitro method, but it shows only direct 
interaction between two proteins. 
A third limitation is of technical nature. The method requires antibodies of good 
quality. Poor antibodies may fail to pull-down protein complexes in cells or may 
bind unspecifically, leading to complications in the interpretation of the co-ip.
The interaction observed in the first co-ip, performed with GFP-tagged MK5 
(Figure 15) proved difficult to reproduce with HA-tagged MK5 (Figure 16 and 
17). Uncertainty concerning the reactivity of DNAJB1 towards GFP coupled with 
this problem of reproducibility favors the conclusion that DNAJB1 and MK5 do 
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not interact with one another. However, the results of the FRET-study point in 
the opposite direction. According to these findings, MK5 and DNAJB1 reside in 
a proximity to each other corresponding to a direct interaction. Again, in these 
studies both proteins are ectopically over-expressed, so the interaction 
observed may be of an artificial nature. To confidently state that MK5 and 
DNAJB1 interact with one another, directly or through additional proteins as 
part of a complex, further studies are needed, such as GST-pulldown and 
repeated endogenous co-ip.
Assessing the in vitro kinase assays, one could argue that the observed 
phosphorylation could actually be phosphorylation of the GST moiety of the 
fusion proteins, and indeed, GST alone should have been included as a control. 
However, previous results have shown that MK5 does not phosphorylate GST 
[results not shown], and so we feel confident that the phosphorylation 
observed is indeed that of DNAJB1. Moreover, GST fusion proteins with 
different parts of the C-terminal domain did not become phosphorylated in 
vitro (Figures 20, 22 and 25), indicating that GST is not phosphorylated by 
MK5. 
Initially, the results of the in vitro kinase assay on individual DNAJB1 domains 
indicated phosphorylation of only J-domain and the first part of the C-terminal 
domain. It was based on these results that candidate phosphoacceptor sites 
were determined (see Figure 20 and 21). When the assay was repeated, this 
time with a more concentrated sample of the G/F-rich domain, additional 
phosphorylation of this domain was observed. Then, when the confusion with 
the GST fusion protein purification was discovered, and elution with Thrombin 
was exchanged for Glutathione, the IVK was repeated yet again, this time with 
higher protein concentrations than before. It turned out that the other two 
domains (the central and distal part of C-terminal domain) were also 
phosphorylated [results not shown]. This corresponded well to the results 
given by the phosphorylation site prediction algorithm, which also reported 
putative phosphoacceptor sites for all domains. 
Based on the results of the IVK on mutants in which phosphoacceptor sites had 
been rendered unphosphorylatable by site directed mutagenesis, it seems that 
all three putative phosphoacceptor sites in the first part of C-terminal are 
phosphorylated by MK5 in vitro. Phosphorylation of the proximal part of C-
terminal appeared to be weaker in each single mutant (S149A, S151A and 
S171A), weaker still in the double mutant (S149A_S151A), and almost 
abolished in the triple mutant (S149A_S151A_S171A), indicating that all three 
sites are phosphorylated by MK5 (see Figure 22 and Figure 28). The weak 
residual phosphorylation in the triple mutant may be due to additional 
phosphoacceptor sites, although no such sites were predicted by the algorithm. 
The S16A mutation within the J-domain did not seem to have an effect on 
phosphorylation, while the Y6A mutation seemed to slightly reduce it. This 
indicates that Y6A might be a phosphoacceptor site, while S16A is not.
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As seen in Figure 21 and appendix E, there are many putative phosphorylation 
sites in DNAJB1, and most of them have not been analyzed by in vitro kinase 
assays. Particularly Serine residues 186 and 196 within the central part of C-
terminal domain and Serine 261 and Threonine 329 within the distal part of C-
terminal appear to be good candidates, but Serine 252 and 330 also hold 
promise. It may turn out that several of these phosphosites are indeed 
phosphorylated by MK5 in vitro, but which sites, if any, are phosphorylated in 
vivo may be a completely different matter. To determine which sites are 
phosphorylated in vivo, detection by phosphospecific antibodies on cell lysates 
or mass spectrometry (MS) can be used.
Somewhat problematic with some of the figures (25 and 28), is the fact that 
phosphorylation of full length protein appears much weaker than 
phosphorylation of the individual domains. This could be due to differences in 
protein concentrations between the samples, which is not unlikely as protein 
concentration of GST-fusion proteins were not measured, only evaluated 
quantitatively by Coomassie staining. It could also be a consequence of 
conformational differences between the individual domains and the full length 
protein, rendering some phosphorylation sites more available than others.
Another problem is the presence of an additional band in MK5, which is of 
approximately the same size as GST-tagged DNAJB1. This complicates the 
interpretation of the results. Also, some samples show faint bands directly 
below the MK5 autophosphorylation band, and this could be contaminants 
present in the protein samples (see Figure 19 and 25).
Finally, WB with anti MK5 should have been performed to confirm the 
presence, and equal loading of MK5 in all samples.
Based on the result of the Luciferase assays it seems that DNAJB1 also 
represses HSF1 in HEK293 cells (Figure 29), and that it downregulates MK5 
somehow (Figure 31 and 32), but it is difficult to say in which way. DNAJB1 
could somehow repress the transcriptional activity of MK5 or interfere with the 
ability of MK5 to act as a trans-activator. To obtain this kind of information, 
further experiments are needed. Additionally, reciprocal experiments should 
have been performed, in which the effect of MK5 on DNAJB1 was investigated. 
Because of  time limitations this was not done, but it remains a possible 
experiment for future studies.
It also seems that MK5 stimulates the transcriptional activity of HSF1 (Figure 
30), but the difference between control cells and cells transfected with MK5 
was too small to be significant, and therefore, further studies are needed to 
elucidate the effect of MK5 on HSF1. Since DNAJB1 inhibits HSF1, the effect of 
MK5 on HSP40 target genes could be monitored by real-time PCR or northern 
blot. One candidate HSP40 target gene is BAG3, which is regulated by HSF1 
[44].
As previously mentioned, the impression when investigating cells under the 
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microscope was that rearrangement of β-tubulin in mock-transfected cells upon 
Forskolin treatment was not observed in cells where DNAJB1 had been knocked 
down by siRNA. In mock-transfected cells, the fine filaments observed in 
untreated cells seemed to aggregate upon Forskolin treatment. This did not 
seem to be the case with DNAJB1 knock down cells. Unfortunately, few pictures 
were taken (Figure 34), and by the time new ones were supposed to be shot, 
the samples had been contaminated by bacteria. Because of time limitations 
the experiment was not repeated. Repetitions of the experiment need to be 
done in order to confirm this tendency. In these repeated experiments, a 
control should be included in the WB of siRNA transfected cells to ensure even 
loading, so as to make sure that the observed reduced expression level of 
DNAJB1 is not a product of uneven loading of the gel. Additionally, cells in 
which DNAJB1 has been knocked down by siRNA should be monitored for 
amount of β-tubulin to investigate whether or not DNAJB1 has an effect on the 
expression levels of β-tubulin in the cell.
Staining for F-actin was also performed, but the procedure was unsuccessful, 
and due to time-limitations, the experiment was not repeated. This is however 
a possible future experiment.
5.1 Conclusions and future perspectives
In this study we have shown that ectopically co-expressed MK5 and DNAJB1 
mainly localize to the nucleus. This could be a result of non-physiological 
conditions produced by ectopic over-expression, and to obtain more confident 
results, immunofluorescence staining of endogenous proteins should be 
performed. 
We also obtained confounding evidence of the physical interaction between 
MK5 and DNAJB1. To confirm or dismiss such interaction, further studies are 
needed, such as GST-pulldown to check for direct interaction between MK5 and 
DNAJB1 and co-immunoprecipitation of the endogenous proteins.
Further we showed that MK5 phosphorylates DNAJB1 in vitro and that Tyrosine 
residue 6 and Serine residues 149, 151 and 171 are in vitro phosphorylation 
sites for MK5. Additionally our results indicate that there are other putative 
phosphorylation sites present within DNAJB1. To investigate the potential of 
these possible phosphoacceptor sites, additional site directed mutagenesis 
should be performed on these sites, followed by in vitro kinase assays. 
Additionally, all in vitro phosphorylation sites should be investigated for their in 
vivo phosphorylation potential by phosphospecific antibodies or MS analysis. 
Additional studies are also required to elaborate the functional implication of 
MK5-mediated phosphorylation of HSP40. 
Luciferase studies indicated that DNAJB1 somehow downregulates the activity 
of MK5. Further studies are needed to elucidate in which way this 
downregulation is mediated. Additionally, reciprocal Luciferase assay of 
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DNAJB1 and MK5 should be performed to investigate the effect of MK5 on the 
activity of DNAJB1.
Aberrant HSP40 expression has been associated with malignant diseases and 
neurodegenerative diseases such as Huntington and ataxia [22]. Whether 
phosphorylation of DNAJB1 by MK5 has an effect on DNAJB1 in these 
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Primers used to separate DNAJB1 into its individual domains [Kostenko 
unpublished results].

















J domain (70 aminoacids), Glycine/Phenylalanine-rich region (35 
aminoacids), C-terminal region
ENTR1A
F 5’GCAGTCGACACCATGGGTAAAG  SalI
      CTACGGGGAGGAATAAGCGGCCGCATA
R 5’TATGCGGCCGCTTATTCCTCCCCGTAG  NotI
ENTR3C
F 5’ AATGGATCCGGCCTAAAGGGGAG  BamHI
      CATGTTTGCTGAGTTCTAACTCGAGACC
R 3’ GGTCTCGAGTTAGAACTCAGCAAACATG  XhoI
ENTR3C
F 5’ AATGGATCCTTCGGTGGCAGAAATC BamHI
       CTCCCTTGAAGAGATCTAACTCGAGACC
R 3’ GGTCTCGAGTTAGATCTCTTCAAGGGAG XhoI
F 5’ AATGGATCCTACAGCGGCTGTAC BamHI
i
      CAAGCCCCACAATTAACTCGAGACC
R 3’ GGTCTCGAGTTAATTGTGGGGCTTG XhoI
F 5’ GCCGGATCCATCTTTAAGAGAGATG BamHI
      CAGGTTCTTCCAATATAGCTCGAGACC
R 3’ GGTCTCGAGCTATATTGGAAGAACCTG XhoI
ii
Appendix B
Single mutations in putative phosphorylation sites in the J-domain and the 
proximal part of C-terminal (aa 106–175) were created by site-directed 
mutagenesis mediated by oligonucleotides. The oligonucleotides/primers used 
to introduce the mutations were as follows:
Primer Sequence
Y6A F 5' AATTCAGTCGACACCATGGGTAAAGACTACGCCCAGACGTTG
Y6A R 5' CAACGTCTGGGCGTAGTCTTTACCCATGGTGTCGACTGAATT
S16A F 5' GTTGGGCCTGGCCCGCGGCGCGGCGGACGAGGAGATCAAG
S16A R 5' CTTGATCTCCTCGTCCGCCGCGCCGCGGGCCAGGCCCAAC
S149A F 5' CTTCACCAACGTGAACTTTGGCCGCGCCCGC
S149A R 5' GCGGGCGCGGCCAAAGTTCACGTTGGTGAAG
S151A F 5' CTCCCGCGCTGCCCAAGAGCCCGCCCGAAAGAAGC
S151A R 5' GCTTCTTTCGGGCGGGCTCTTGGGCAGCGCGGGAG
S171A F 5' CACGACCTTCGAGTCGCCCTTGAAGAGATC
S171A R 5' GATCTCTTCAAGGGCGACTCGAAGGTCGTG
The rest of the procedure is identical to the protocol given in section 2.2.13.
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pENTR3C-CREB was constructed from pcDNA3-CREB and pENTR3C by 
digestion of restriction endonucleases. 
Several different incubation times and nucleases were tested, and buffers 
changed accordingly. The successful restriction cutting was accomplished by 
the following set-up:
Reagent Sample 1 Sample 2
10 x TA buffer 2  µl 2  µl
pcDNA3-CREB 1  µg
pENTR3C 0.5  µg
KpnI 1 µl 1  µl
NotI 0.5  µl 0.5  µl
BSA 0.7  µl 0.7  µl
ddH2O To 20  µl To 20  µl
The samples were incubated at 37 °C o.n.




pENTR1A-HSF1 was constructed from pEGFP-N1-HSF1 and pENTR1A by 
digestion  of restriction endonucleases.
Reagent Sample 1 Sample 2
Neb buffer 2 2 µl
Neb buffer 3 2 µl
pEGFP-N1-HSF1 1 µg
pENTR1A 1 µg
EcorI 1 µl 1 µl
SalI 1 µl
XhoI 1 µl
ddH2O To 20 µl To 20 µl
The samples were incubated at 37 °C for 2 hours
The rest of the procedure was identical to the description in section 3.2.14
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Appendix E    
Predicted phosphorylation sites in DNAJB1 by NetPhos 2.0
     Serine predictions
Name           Pos   Context    Score  Pred
_________________________v_________________
Sequence        16   ARGASDEEI  0.996  *S*
Sequence        56   YDVLSDPRK  0.593  *S*
Sequence        75   GLKGSGPSG  0.031    .
Sequence        78   GSGPSGGSG  0.817  *S*
Sequence        81   PSGGSGGGA  0.143    .
Sequence        89   ANGTSFSYT  0.119    .
Sequence        91   GTSFSYTFH  0.089    .
Sequence       132   DDPFSGFPM  0.385    .
Sequence       149   NFGRSRSAQ  0.888  *S*
Sequence       151   GRSRSAQEP  0.985  *S*
Sequence       171   DLRVSLEEI  0.995  *S*
Sequence       177   EEIYSGCTK  0.010    .
Sequence       186   KMKISHKRL  0.971  *S*
Sequence       196   PDGKSIRNE  0.972  *S*
Sequence       228   GDQTSNNIP  0.009    .
Sequence       252   KRDGSDVIY  0.838  *S*
Sequence       261   PARISLREA  0.994  *S*
Sequence       330   IPQTSRTVL  0.889  *S*
_________________________^_________________
ix
                Threonine predictions
Name           Pos   Context    Score  Pred
_________________________v_________________
Sequence         8   DYYQTLGLA  0.607  *T*
Sequence        88   GANGTSFSY  0.164    .
Sequence        93   SFSYTFHGD  0.040    .
Sequence       114   NPFDTFFGQ  0.334    .
Sequence       142   MGGFTNVNF  0.056    .
Sequence       165   DPPVTHDLR  0.368    .
Sequence       180   YSGCTKKMK  0.739  *T*
Sequence       205   DKILTIEVK  0.655  *T*
Sequence       216   WKEGTKITF  0.355    .
Sequence       219   GTKITFPKE  0.041    .
Sequence       227   EGDQTSNNI  0.190    .
Sequence       270   LCGCTVNVP  0.018    .
Sequence       275   VNVPTLDGR  0.129    .
Sequence       280   LDGRTIPVV  0.036    .
Sequence       307   PLPKTPEKR  0.686  *T*
Sequence       329   RIPQTSRTV  0.962  *T*
Sequence       332   QTSRTVLEQ  0.029    .
_________________________^_________________
      
x
        Tyrosine predictions
Name           Pos   Context    Score  Pred
_________________________v_________________
Sequence         5   MGKDYYQTL  0.118    .
Sequence         6   GKDYYQTLG  0.947  *Y*
Sequence        24   IKRAYRRQA  0.033    .
Sequence        31   QALRYHPDK  0.029    .
Sequence        52   IAEAYDVLS  0.220    .
Sequence        67   IFDRYGEEG  0.386    .
Sequence        92   TSFSYTFHG  0.604  *Y*
Sequence       176   LEEIYSGCT  0.543  *Y*
Sequence       256   SDVIYPARI  0.141    .
_________________________^_________________
xi
